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Abstract 
Pyrrole-imidazole (Py-Im) polyamides are programmable oligomers that bind to the 
minor groove of DNA in a sequence-specific manner at affinities comparable to natural DNA-
binding proteins. Hairpin polyamides have been shown to localize within the nucleus of live 
cells, disrupt protein-DNA interactions, and modulate endogenous gene expression. Cyclic 
polyamides display further enhanced DNA binding affinities and exhibit similar gene regulatory 
effects, but investigations into their biological activity have been limited by the lack of effective 
synthetic methods. Herein, we demonstrate the efficient synthesis of a focused library of cyclic 
polyamide utilizing a novel microwave-assisted solid-phase technique. The orthogonal protection 
strategy allowed for selective turn modifications, and the mild cleavage conditions gave access to 
polyamide cores beginning with a C-terminal imidazole. In addition to expanding our synthetic 
repertoire, we further examined the cytotoxicity and cell uptake profiles of the cyclic polyamide 
variants, which highlighted the significant changes in biological activity resulting from minor 
structural modifications. Molecular recognition of the polyamide turn unit was also explored by 
installing heteroatom substituents at the -position. Interestingly, while none of the fluoro, 
hydroxyl, or amino derivatives increased turn specificity, the (S)-fluoro turn exhibited better 
tolerance for binding a C•G pair. Finally, we optimized the synthesis of several biologically 
active hairpin polyamides on a 50-mg scale and examined their antitumor activity in mice 
xenograft models.  
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1.1 Deoxyribonucleic Acid (DNA) 
Deoxyribonucleic acid is the double helical biopolymer that encodes all heritable 
information necessary for the development and function of all living organisms. Each strand of 
DNA is composed of a phosphodiester deoxyribose sugar backbone that links together a 
sequence of four nucleotides - deoxythymine (T), deoxyadenine (A), deoxycytosine (C) and 
deoxyguanine (G) (Fig. 1.1). Two strands of DNA intertwine in an antiparallel fashion to form a 
double helix through hydrogen bonding between the Watson-Crick base pairs, such that T pairs 
with A and C pairs with G. Depending on the sequence context and physiological conditions, 
DNA exists in several different conformations, including A-form, B-form and Z-form. In the 
most commonly observed B-DNA, the right-handed helix displays ten base pairs per turn with 
the plane of each hydrogen-bonded base pair lying perpendicular to the helical axis.
1
 The overall 
asymmetric DNA duplex can be further subdivided into a wide major groove and a narrow minor 
groove, each offering sequence-specific chemical functionalities for DNA recognition. 
 
1.2 Regulation of Gene Expression by Transcription Factors 
A human cell nucleus contains 3 x 10
9
 base pairs of DNA that encodes 20,000 to 25,000 
protein-coding genes.
2
 The gene expression process begins with the transcription of genomic 
DNA into an mRNA template, which is then translated into the final protein product. Although 
every cell in any given organism contains the same genome, the regulation of gene expression 
dictates the production levels of various proteins that results in the diverse phenotypes found in 
different cell types. The gene expression profile within each cell is also continually modulated, 
depending on internal factors (e.g. cell cycle progression) as well as external stimuli (e.g. 
intracellular signaling, environmental stress, etc.).  
23 
 
 
Figure 1.1 X-ray crystal structure of double-stranded DNA (PBD 1BNA) and examination of 
hydrogen bonding between Watson-Crick base pairs. 
 
 
The regulation of gene expression at the transcriptional level can be achieved by three 
general modes - direct binding of a control factor to the target gene interactions between a 
control factor with the transcription machinery, or modifications in the tertiary DNA structure 
and thus accessibility of the target site. The most direct method for a protein to modulate gene 
expression is by directly interacting with specific binding sites (i.e. promoters, enhancers, 
repressors, etc.) found in the genome. The mechanism for regulating transcription through these 
interactions are often complex and, by recruiting or blocking RNA polymerase, either 
transcription activation or repression may be achieved.  
24 
 
Transcription factors are a class of DNA-binding proteins that participate in the 
transcriptional regulation of gene expression. By interacting with gene promoter or enhancer 
regions, which are generally upstream of the transcription start site, transcription factors 
modulate the occurrence of RNA polymerase binding events and thus control the level of gene 
transcription. Most transcription factors possess a DNA-binding domain that recognizes and 
interacts with either the minor groove, major groove, or both, of a specific DNA sequence. 
TATA-binding protein (TBP) and Lef-1 are examples of minor groove binding transcription 
factors,
3,4
 whereas NF-B, Myc/Max, AR, and Ets-1 recognize the major groove of DNA. 5–8 
 
Figure 1.2 X-ray crystal and NMR structures of transcription factor-DNA complexes: TBP 
(PBD 1TGH), NFB (PBD 1VKX), AR (PBD 1R4I), LEF-1 (PBD 2LEF), Myc/Max (PBD 
1NKP), and ETS-1 (PBD 2STW). 
25 
 
1.3 DNA-Binding Natural Products 
In addition to the transcription factors described above, there are numerous small 
molecule natural products that recognize and bind DNA in a sequence-specific fashion. Four 
particular examples are given in Figure 1.3. Chromomycin A3 binds to 5’-GGCC-3’ sequences 
in the DNA minor groove in a 2:1 ligand:DNA stoichiometry, and has exhibited biological 
activity by interfering with replication and transcription.
9
 Calicheamicin oligosaccharide 
recognizes the sequence 5’-TCCT-3’ and binds to the minor groove of DNA in a monomeric 
fashion.
10
 Actinomycin D intercalates DNA specifically at 5’-GC-3’ sites in a 1:1 ligand:DNA 
stoichiometry, and is known inhibit transcription and potentially DNA replication.
11,12 
 
 
Figure 1.3 Chemical structures of DNA-binding natural products: chromomycin A3, 
actinomycin, calicheamicin oligosaccharide, and distamycin. 
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Figure 1.4 X-ray crystal structures displaying the molecular recognition of DNA by netropsin 
(PBD 6BNA) and distamycin (PBD 2DND in a 1:1 complex and PBD 378D in a 2:1 complex). 
 
Distamycin and netropsin are oligopeptides that bind to AT tracts of DNA, which contain 
three and two N-methylpyrrole (Py) carboxamide units, respectively.
13,14
 While distamycin can 
bind to DNA in either a 1:1 or 2:1 ligand:DNA stoichiometry, netropsin is only known to form a 
1:1 ligand:DNA complex (Fig. 1.4).
15-17
 The width and depth of the DNA minor groove is altered 
upon binding of the 1:1 and 2:1 complexes. Upon ligand binding in a 1:1 stoichiometry, the 
minor groove of DNA is narrowed and deepened. The 2:1 complex formed by distamycin is an 
antiparallel dimer that widens the minor groove. 
27 
 
1.4 Recognition of the DNA Minor Groove by Py-Im Polyamides 
Based on the simple natural product distamycin A, a new class of programmable 
heterocyclic oligomers known as Py-Im polyamides has been developed to distinguish all four 
base pairs with high affinity and sequence specificity for the minor groove of DNA.
18,19
 In an 
early proof-of-principle experiment, N-methylimidazole (Im) was incorporated into a 
distamycin-like Im-Py-Py-Dp structure, which was shown to recognize the 5’-WGWCW-3’ 
sequence in a 2:1 ligand:DNA stoichiometry.
20,21
 This not only expanded the sequence 
recognition capabilities of polyamides, but these side-by-side antiparallel ring pairings would 
also form the basis for recognition of all four DNA base pairs in the minor groove (Fig. 1.5). 
When Im is across from Py to form an Im / Py pair, the endocyclic secondary amine of Im 
presents a lone pair of electrons that can form a favorable hydrogen bonding interaction with the 
exocyclic amine of guanine, so binding to G•C is preferred. Conversely, Py / Im is selective for 
C•G, whereas Py / Py recognizes T•A or A•T. Distinction between T•A and A•T was 
accomplished by introducing the N-methyl-3-hydroxypyrrole (Hp) monomer.
22
 Hp projects an 
exocyclic OH group toward the minor groove floor that is sterically accommodated in the cleft of 
the T•A base pair and forms a favorable hydrogen bonding interaction with one of the thymine 
carbonyl lone pairs, and the Hp / Py pair therefore shows preference for T•A over A•T.23 
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Figure 1.5 Molecular recognition of the DNA minor groove by Py-Im polyamides. (A) 
Schematic illustration of the polyamide ImHpPyPy-(R)
-H2N-γ-ImHpPyPy-(+)-IPA binding to its 
target sequence 5’-WGTACW-3’. Potential hydrogen binds are indicated by dashed lines. Ball-
and-stick representation of the polyamide bound to DNA is shown below. (B) Ball-and-stick 
symbols and abbreviations listed below the corresponding chemical moieties, which will be used 
throughout this dissertation 
 
In addition to completing the pairing rules for the Watson-Crick base pairs, a -
aminobutyric acid (GABA) linker has been introduced to covalently attach the two polyamide 
oligomers in an antiparallel fashion to form a hairpin polyamide structure.
24
 This hairpin “turn” 
unit prepaid the entropic cost for polyamide binding in a 2:1 ligand:DNA stoichiometry, and 
improve the DNA binding affinity by two orders of magnitude.
25
 Since hairpin polyamides are 
known to occasionally align N- to C-terminus against DNA in a 3’ to 5’ direction, commonly 
29 
 
referred to as “reverse” binding, a (R)-2,4-diaminobutyric acid linker was used instead of the 
GA turn, which not only increased binding affinity but also enforced the “forward” binding 
orientation of polyamide N- to C- terminus aligning to DNA in a 5’ to 3’ direction.26,27 By 
shifting the turn -amine to the -position, the (R)-3,4-diaminobutyric acid linker has also been 
utilized and exhibits better tolerance for turn conjugation.
28
 Hairpin polyamides containing eight 
heterocycles linked by a turn unit can target six DNA base pairs, and serve as the typical 
substrates used in our biological studies. By fully preforming the 2:1 complex, cyclic polyamides 
containing a second turn unit display further enhanced binding affinities and have been recently 
examined for their biological activity.
29–31 
 
1.5 Polyamide Regulation of Gene Expression in Cell Culture 
The regulation of gene expression using programmable DNA-binding oligomers presents 
a promising new approach towards molecular medicine. Hairpin polyamides containing a GABA 
linker bind to their match DNA sequences at subnanomolar concentrations comparable to 
endogenous DNA-binding proteins.
18,19 
Along with the modular sequence recognition 
characterized by the pairing rules, polyamides can be designed to target an array of transcription 
factor binding sites in gene promoter sequences and thereby disrupt downstream transcriptional 
events (Fig. 1.6). Towards this goal, the nuclear localization of polyamide-fluorophore 
conjugates have been confirmed by confocal microscopy and the incorporation of a isophthalic 
acid (IPA) moiety at the C-terminus have yielded polyamide conjugates with high affinity and 
improved nuclear permeability.
32–34 
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Figure 1.6 Modulation of gene expression by Py-Im polyamides. (A) Schematic diagram 
showing inhibition of VEGF gene transcription by disrupting HIF-1 binding to HRE. (B) 
Polyamide 1 binding to 5’-ATACGT-3’ sequence found in HRE enhancer. (C) Schematic 
illustration of the androgen receptor transcription complex. (D) Consensus ARE-targeted by 
match polyamide 3. (E) Chemical structure and ball-and-stick models of polyamides 1 (VEGF 
match), 2 (VEGF mismatch), 3 (AR match), and 4 (AR mismatch), along with 5 and 6 that 
exhibit improved activity towards regulating AR-driven gene transcription. 
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Hypoxia inducible factor 1 (HIF-1) is a transcription factor that drives gene expression 
in response to low oxygen environments by binding to the hypoxic response element (HRE) 
consensus sequence 5’-TACGTG-3’. Among these activated genes is the vascular endothelial 
growth factor (VEGF) responsible for tumor vascularization. HeLa and U251 cells dosed with 1, 
which binds to a subset of HREs, exhibited a reduction in deferoxamine (DFO) induction of the 
VEGF gene.
35,36
 In contrast, treatment with polyamide 2 that does not bind the HRE did not 
result in a statistically significant change in VEGF expression. On a global scale, microarray 
analysis indicated that 1 downregulated a subset of genes activated by DFO induction. 
Chromatin immunoprecipitation (ChIP) experiments further demonstrated a decrease in 
occupancy of HIF-1 at the VEGF HRE following treatment with 1, supporting a sequence-
dependent mechanism. 
The androgen receptor (AR) transcription factor regulates gene expression in response to 
steroid hormones, such as testosterone, by binding to the androgen response element (ARE) 
consensus sequence 5’-GGTACAnnnTGTTCT-3’. AR-driven gene expression is essential to the 
development and progression of prostate cancer. A particularly noteworthy AR-activated gene is 
prostate specific antigen (PSA), which is a well-studied marker gene with high correlation to the 
presence of prostate cancer. In the presence of dihydrotestosterone (DHT), LNCaP prostate 
cancer cells treated with 3 targeted to the ARE half-site 5’-WGWWCW-3’ exhibited a 
suppressed induction of PSA transcription.
37
 On the other hand, mismatch polyamide 4, which 
binds to the 5’-WGWCGW-3’ sequence, produced a much smaller effect on PSA mRNA levels. 
Microarray experiments showed reduced DHT induction by 3 for a subset of DHT-induced 
genes, whereas ChIP assays again support the disruption of transcription factor-DNA interactions 
as a plausible mechanism for polyamide modulation of gene expression. In a follow-up study, 
32 
 
LNCaP cells were treated with hairpin polyamide 5 containing an acetylated -amino turn and 
cyclic polyamide 6 under DHT induction, and both ARE-targeted compounds exhibited gene 
regulatory effects similar to 3 at ten-fold lower concentrations.
31
 Following these two pioneering 
studies, the modulation of gene expression mediated by the glucocorticoid receptor, NFkB, and 
estrogen receptor (to be discussed in greater detail in Chapter 4) has also been achieved.
38,39 
 
1.6 Allosteric Modulation of Transcription Factor-Driven Gene Expression 
Although HIF-1 and AR both bind to the major groove of DNA, minor groove binding 
Py-Im polyamides may successfully perturb transcription factor-DNA interfaces and thus alter 
gene expression via allosteric regulation of the DNA-binding sites.
40
 The process of promoter 
recognition involves a series of specific interactions between transcription factors and promoter 
sites to form stable protein-DNA complexes that allow for transcription initiation. These protein-
DNA interactions are generally weak and dissociate readily, and the capacity to stabilize these 
otherwise weak interactions is likely crucial to transcriptional control that often requires 
cooperative assembly of multiple factors.
41
 In other words, the sequence-specific binding of a 
transcription factor induces perturbations to the local DNA structure, which creates the optimal 
shape for binding of the next transcription factor and so forth. This allosteric modulation of 
protein-DNA specificity on a gene enhancer site is elegantly displayed by the model structure of 
the interferon-beta enhancesome (Fig. 1.7).
42
 In this model, eight different transcription factors 
(ATF-2, c-Jun, IRF-3A, IRF-7B, IRF-3C, IRF-7D, p50, and RelA) are cooperatively assembled 
on the enhancer without any direct protein-protein contacts. Each transcription factor binds 
specifically to four to eight base pairs, and inhibiting the binding of any one of these proteins 
may disrupt the association of the entire complex and thereby its transcription activation activity. 
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Figure 1.7 A composite model illustrating the cooperative assembly of interferon- 
enhancesome, created from overlaid x-ray crystal structures (PBD 2O6G, 2O61). 
 
A high-resolution X-ray crystal structure of cyclic polyamide 6 in complex with the DNA 
sequence 5’-CCAGTACTGG-3’ reveals the significant alterations in DNA structure upon 
polyamide binding (Fig. 1.8).
43
 Compared to unliganded B-form DNA,
44
 the 10 base pair 
oligonucleotide bound by 6 experiences a substantial widening of the minor groove and 
compression of the major groove by more than 4 Å in both directions. Furthermore, the overall 
DNA helix in the polyamide-bound structure is bent by > 15
o
 towards the major groove. This 
distortion in the geometry of the minor and major grooves is highlighted by a slice through the 
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short axis of the DNA helix in the uncomplexed and complexed structures. Polyamide binding to 
the minor groove of DNA, therefore, converts the normally wide and shallow major groove to a 
narrow and deep cleft that can no longer accommodate the association of a transcription factor. 
This allosteric modulation of the DNA helix offers a mechanistic model for the perturbation of 
transcription factor-DNA interactions by Py-Im polyamides. 
 
Figure 1.8 Polyamide perturbation of DNA structure. (A) X-ray -crystal structure of native DNA 
at 0.98 Å resolution (PBD 1D8G). (B) X-ray crystal structure of polyamide/DNA complex at 
0.95 Å resolution (PBD 3OMJ). (C) DNA bending upon polyamide binding (blue) vs. unbound 
DNA (yellow). (D) Minor groove widening (top) and major groove narrowing (bottom) of 
polyamide/DNA complex (blue) relative to native DNA (yellow).  
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1.7 Scope of this Thesis 
The work in this thesis is aimed at the further advancement in polyamide synthesis 
technology to gain access towards novel structural derivatives. In our ongoing efforts in studying 
the biological activity of Py-Im polyamides, the pronounced effects of minor structural 
modifications have been repeatedly observed in both cell culture and animal models. The 
efficient synthesis of polyamide derivatives has, therefore, proven instrumental to our continued 
biological investigations. In Chapter 2, we describe a newly developed method utilizing Fmoc 
chemistry to synthesize cyclic polyamides under microwave-assisted solid-phase conditions. The 
modular approach provided quick and reliable access to a focused library of macrocyclic 
derivatives, which were tested and compared for their cytotoxicity and uptake properties in two 
cancer cell lines. In Chapter 3, we explored the molecular recognition properties of the 
polyamide turn unit by substitution with different heteroatoms at the -position. The fluoro, 
hydroxyl, and amino turn derivatives were synthesized and measured for their binding affinities 
and preferences by DNase I footprinting and DNA thermal denaturation assays. In Chapter 4, we 
describe in detail the optimized and expedited synthesis of several hairpin polyamides and 
examine their antitumor activity in vivo. 
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Synthesis of Cyclic Py-Im Polyamide Libraries 
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Abstract 
Cyclic Py-Im polyamides containing two GABA turn units exhibit enhanced DNA 
binding affinity, but extensive studies of their biological properties have been hindered due to 
synthetic inaccessibility. A facile modular approach towards cyclic polyamides has been 
developed via microwave-assisted solid-phase synthesis of hairpin amino acid oligomer 
intermediates followed by macrocyclization. A focused library of cyclic polyamides 1–7 targeted 
to the androgen response element (ARE) and the estrogen response element (ERE) were 
synthesized in 12-17% overall yield. The Fmoc protection strategy also allows for selective 
modifications on the GABA turn units that have been shown to improve cellular uptake 
properties. The DNA binding affinities of a library of cyclic polyamides were measured by DNA 
thermal denaturation assays and compared to the corresponding hairpin polyamides. Fluorescein-
labeled cyclic polyamides have been synthesized and imaged via confocal microscopy in A549 
and T47D cell lines. The IC50s of compounds 1–7 and 9–11 were determined, revealing 
remarkably varying levels of cytotoxicity. 
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2.1 Introduction 
The selective modulation of eukaryotic gene expression by small molecules may have 
important implications in the field of chemical biology and human medicine. Pyrrole-imidazole 
polyamides are a class of synthetic ligands that can be programmed to bind the minor groove of 
specific DNA sequences.1 Antiparallel, side-by-side N-methylpyrrole (Py) and N-
methylimidazole (Im) carboxamides (Im/Py) pairs distinguish G·C from C·G base pairs, N-
methyl-3-hydroxypyrrole (Hp)/Py shows specificity for T·A over A·T, whereas Py/Py pairs are 
specific for both T·A and A·T.2–5 By linking two strands of these heterocyclic oligomers via a -
amino butyric acid (GABA) turn unit, hairpin Py-Im polyamides can be programmed to bind a 
large library of DNA sequences with affinities comparable to natural DNA-binding proteins.6–8 
Hairpin polyamides have been shown to localize to the nuclei of living cells, and regulate 
endogenous gene expression by disrupting protein / DNA interfaces.9–17 Cyclic polyamides 
containing a second GABA turn unit exhibit further enhanced DNA binding properties.18–21 We 
have recently demonstrated their gene regulatory effects on AR-activated gene expression in 
prostate cancer models.22 
This discovery has opened a new area of research towards transcriptional regulation with 
small molecules, but the relative synthetic inaccessibility of cyclic polyamides has remained a 
bottleneck for examining libraries of structural variants that would modulate affinity, cell uptake 
and biological activity. Initial solid-phase methods were low yielding, and required substantial 
pre-modifications of the PAM resin.18–20 While the solution-phase synthesis of cyclic polyamides 
remains useful in large-scale target-oriented synthesis, it has limited practicality towards libraries 
for screening biological activities.22 The recent report by Morinaga et al. offers a modular 
approach to achieve cyclic polyamides by intramolecular coupling of a cysteine and a 
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chloroacetyl residue, but the modification of the optimal three-carbon GABA turn into a sulphur-
containing four-atom linker compromises its DNA binding affinity and may alter its biological 
properties.23 
We report here a solid-phase polyamide synthesis of a key hairpin amino acid oligomer  
intermediate, which followed by intramolecular cyclization, affords cyclic polyamides 1–8 in 
good yields. The polyamides were synthesized step-wise on 2-chlorotrityl resin. The modular 
approach led to rapid access of a focused library of cyclic polyamides 1–7 with various core 
sequences and turn unit modifications. The utilization of Fmoc chemistry allowed for 
differentially protected turn units, which were modified selectively to complement existing 
cellular imaging and cell uptake enhancement technologies.24 We examined the DNA-binding 
properties and cytotoxicity profiles of compounds 1–11, and the cellular localization of cyclic 
polyamides 12–14 by fluorescence microscopy.  
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Scheme 2.1 Microwave-assisted synthesis of cyclic polyamides 1-7 
 
1
All PyBOP-mediated coupling conditions were performed under microwave-assisted conditions (see Table 1). 
2
Reagents and conditions: (i) 50% piperidine, DMF; (ii) FmocPyOH, PyBOP, DIEA, DMF; (iii) 50% piperidine, 
DMF; (iv) FmocPyOH, PyBOP, DIEA, DMF; (v) 50% piperidine, DMF; (vi) FmocImOH, PyBOP, DIEA, DMF; 
(vii) 50% piperidine, DMF; (viii) Z--Dab(Fmoc)-OH (for 1–6) or Boc--Dab(Fmoc)-OH (for 7), PyBOP, DIEA, 
DMF; (ix) 50% piperidine, DMF; (x) FmocPyOH, PyBOP, DIEA, DMF; (xi) 50% piperidine, DMF; (xii) 
FmocPyOH, PyBOP, DIEA, DMF; (xiii) 50% piperidine, DMF; (xiv) FmocPyOH (for 1–3) or FmocImOH (for 4–
7), PyBOP, DIEA, DMF; (xv) 50% piperidine, DMF; (xvi) FmocImOH, PyBOP, DIEA, DMF; (xvii) 50% 
piperidine, DMF; (xviii) Z--Dab(Fmoc)-OH (for 1 & 4 & 7) or Fmoc-GABA-OH (for 2 & 5) or Boc--
Dab(Fmoc)-OH (for 3 & 6), PyBOP, DIEA, DMF; (xix) 30% HFIP, DCM; (xx) 20% piperidine, DMF; (xxi) DPPA, 
DIEA, DMF; (xxii) 10% TFMSA, TFA (for 1, 2, 4 & 5) or TFA (for  3, 6 & 7).  
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2.2 Results and Discussion 
I. Microwave-Assisted Solid-Phase Synthesis 
Due to previously observed decomposition of the conjugated C-terminal free carboxylic 
acid in polyamide intermediates, 2-chlorotrityl-chloride (2-Cl-Trt-Cl) resin was chosen for its 
mild synthesis and cleavage conditions. Polyamide synthesis on this resin has been previously 
reported by Aldrich-Wright and co-workers, but a resin-bound -alanine linker was used in both 
instances, and a new loading procedure was therefore needed.
25,26
 2-Cl-Trt-Cl resin was first 
loaded with the Fmoc-protected Py monomer in N,N-dimethylformamide (DMF) and capped 
with methanol. Resin substitution levels were determined by the Fmoc test and confirmed by 
weighing the dry mass of the loaded resin. Fmoc deprotection was achieved using a 50% 
piperidine in DMF solution. In light of the recent improvements in both efficiency and yield, the 
couplings were performed under microwave-assisted conditions using the desired PyBOP-
activated monomers.
27 
Initial syntheses performed at 60 
o
C led to premature cleavage of 
intermediates off the 2-Cl-Trt resin, and 50 
o
C couplings were therefore preferable.  The 
challenging Im to Py coupling required an FmocPyImOH dimer, which was obtained via an 
optimized procedure by Weltzer and Wemmer.
28 
The deprotection and coupling conditions are 
detailed in Table 1. This 2-step deprotection-coupling procedure was repeated until the desired 
polyamide sequence was achieved. To build the small library of polyamides in a modular 
fashion, the resin was split into different batches at corresponding steps for further derivatization.  
Upon completion, the N-terminal Fmoc-protected polyamide oligomer was cleaved from the 
resin with 30% hexafluoroisopropanol (HFIP) in dichloromethane (DCM), concentrated in 
vacuo, and the resulting residue was subjected to a 20% piperidine solution to remove the Fmoc 
group. Direct cleavage of the free-amine polyamide oligomer was attempted, but found to be 
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ineffective due to poor solubility of the zwitterion intermediate in the cleavage solution. After 
purification by high-performance liquid chromatography (HPLC), the desired polyamide 
intermediates 18–24 were obtained in 31–40% yields. 
 
Table 2.1 Standard Fmoc deprotection and microwave-assisted coupling times for solid-phase 
polyamide synthesis. 
 
 
Resin-Bound 
Nucleophile 
Deprotection 
Times1 
Coupling Times2 (min) 
Py Im GABA/-Ala 
Py 3 x 10 min 20 20 20 
Im 3 x 10 min IR3 30 30 
GABA/-Ala 2 x 5 min 20 20 20 
 
1
All deprotections were performed in 50% piperidine in DMF. 
2
All coupling reactions were 
conducted under microwave-assisted conditions at 50 
o
C with a 0.3M solution of the activated 
monomers (3 eq. monomer acid, 3 eq. PyBOP, 8 eq. DIEA, DMF). 
3
FmocPyOH coupling onto 
resin with N-terminal Im was incomplete even at 60 
o
C for up to 1h. Synthesis of polyamide 
sequences that require this linkage should use the FmocPyImOH dimer instead, demonstrated 
later in the synthesis of 8. 
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Table 2.2 Summary table of MALDI-TOF data and synthetic yields for cyclic polyamides 1–8 
and intermediates 18–25. 
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Scheme 2.2 Preparation of cyclic polyamides 9–11 
 
 
 
1
Reagents and conditions: (i) BzOH, PyBOP, DIEA, DMF; (ii) 10% TFMSA, TFA. 
 
 
II. DPPA-Mediated Macrocyclization 
The polyamide macrocyclization step was achieved by a DPPA-mediated ring-closing 
reaction between the N-terminal amino group and the C-terminal carboxylic acid. This method 
was first employed by Cho et al. in the synthesis of cyclic polyamides.
18,29,30
 In order to obtain a 
general work-up procedure applicable to polyamides of various lipophilicities, 
diisopropylethylamine (DIEA) was used as the base in place of sodium bicarbonate (NaHCO3) in 
the original conditions.
31 
Deprotection of the turn units with trifluoromethanesulfonic acid 
(TFMSA) or trifluoroacetic acid (TFA), followed by HPLC purification, afforded polyamides 1–
7 in 37–43% yields over 2 steps.  
49 
 
III. Selective Derivatization of Cyclic Polyamide Turn Units  
By taking advantage of the Fmoc protection scheme, the two GABA -amino groups in 3 
were differentially protected. This is further highlighted in 6 and 7, which share the same 
asymmetric polyamide core targeted to the 5’-WGGWCW-3’ sequence, and allowed for the 
selective conjugation of a benzoic acid moiety on a single turn unit in polyamides 9–11 that has 
been recently developed to enhance the cellular localization properties of hairpin polyamides.
24
 
Mono-substituted benzyl carbamate (Cbz) polyamides 3, 6 and 7 were chosen as targets based on 
unpublished results indicating Cbz-functionalized polyamides are biologically active (Supp. Fig. 
S16). Cyclic polyamides 12–14 with a fluorescein dye were synthesized in a similar fashion, and 
imaged in living cells via fluorescence microscopy. Furthermore, both the solubility and the 
pharmacokinetic profiles of cyclic polyamides have been shown to be highly dependent on subtle 
structural modifications, and this method allows for the modular synthesis of these structural 
variants in an efficient manner.
31–33
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Scheme 2.3 Preparation of cyclic polyamides 12–14 
 
 
1
Reagents and conditions: (i) FITC, DIEA, DMF; (ii) 10% TFMSA, TFA. 
 
 
 
IV. Synthesis of Cyclic and Hairpin Polyamides with C-terminal Imidazole Units 
 Previously established solid-phase polyamide synthesis methods have been generally 
limited to sequences beginning with a pyrrole monomer.
34,35 
Solid-phase synthesis of polyamides 
starting with imidazole units on the commonly used Kaiser oxime resin have been low yielding, 
mainly attributed to the sensitivity of the oxime-imidazole linkage that lead to premature 
cleavage of resin-bound intermediates. The addition of an aliphatic linker (e.g. Boc--Ala-PAM 
resin) circumvents this issue, but previous studies on hairpin polyamides with C-terminal -
alanine motifs have shown reduced cellular uptake properties and thus diminished gene 
regulatory effects of these products.
9
 Using the microwave-assisted conditions reported above, 
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cyclic polyamide 8 targeted to the 5’-WCGWGW-3’ sequence found in E-Box binding sites have 
been synthesized in 13% yield overall.  
 
Initial attempts starting with FmocImOH-loaded resin resulted in undesired cleavage 
during subsequent steps, and so syntheses began with loading of the FmocPyImOH dimer onto 
2-chlorotrityl resin. After deprotection-coupling of the corresponding monomer units, followed 
by resin cleavage and Fmoc removal, polyamide intermediate 25 was isolated by HPLC 
purification in 34% yield. DPPA-mediated cyclization of 25, followed by Cbz deprotection 
afforded cyclic polyamide 8 in 39% yield over 2 steps. Hairpin polyamide 17 was synthesized in 
a similar stepwise manner to afford the Im-capped, C-terminal acid intermediate, which was then 
coupled to a 3,3’-diamino-N-methyldipropylamine linker, followed by isophthalic acid 
conjugation, Boc deprotection, and isolated in 24% yield over 16 steps (Scheme 2.5).  This is a 
step forward which allows for the synthesis of both cyclic and non--alanine-linked hairpin 
polyamides with sequences beginning with an imidazole unit, further expanding the scope of 
targetable DNA sequences and inhibition of transcription factor-mediated gene expression by 
Py-Im polyamides. 
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Scheme 2.4 Preparation of cyclic polyamide 8 
 
 
 
1
All PyBOP-mediated coupling conditions were performed under microwave-assisted conditions (see Table 1). 
2
Reagents and conditions: (i) 50% piperidine, DMF; (ii) FmocPyOH, PyBOP, DIEA, DMF; (iii) 50% piperidine, 
DMF; (iv) FmocPyOH, PyBOP, DIEA, DMF; (v) 50% piperidine, DMF; (vi) Z--Dab(Fmoc)-OH, PyBOP, DIEA, 
DMF; (vii) 50% piperidine, DMF; (viii) FmocImOH, PyBOP, DIEA, DMF; (ix) 50% piperidine, DMF; (x) Fmoc--
Ala-OH, PyBOP, DIEA, DMF; (xi) 50% piperidine, DMF; (xii) FmocPyImOH, PyBOP, DIEA, DMF; (xiii) 50% 
piperidine, DMF; (xiv) Z--Dab(Fmoc)-OH, PyBOP, DIEA, DMF; (xv) 30% HFIP, DCM; (xvi) 20% piperidine, 
DMF; (xvii) DPPA, DIEA, DMF; (xviii) 10% TFMSA, TFA. 
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Scheme 2.5 Preparation of hairpin polyamide 17 
 
 
1
All PyBOP-mediated coupling conditions were performed under microwave-assisted conditions (see Table 1). 
2
Reagents and conditions: (i) 50% piperidine, DMF; (ii) FmocPyOH, PyBOP, DIEA, DMF; (iii) 50% piperidine, 
DMF; (iv) FmocPyOH, PyBOP, DIEA, DMF; (v) 50% piperidine, DMF; (vi) Boc--Dab(Fmoc)-OH, PyBOP, 
DIEA, DMF; (vii) 50% piperidine, DMF; (viii) FmocImOH, PyBOP, DIEA, DMF; (ix) 50% piperidine, DMF; (x) 
Fmoc--Ala-OH, PyBOP, DIEA, DMF; (xi) 50% piperidine, DMF; (xii) PyImOH, PyBOP, DIEA, DMF; (xiii) 30% 
HFIP, DCM; (xiv) 3,3’-diamino-N-methyldipropylamine, PyBOP, DMF; (xv) Isophthalic acid, PyBOP, DIEA, 
DMF; (xvi) TFA. 
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V. Thermal Stabilization of DNA Duplexes by Polyamides  
Py-Im polyamide-DNA binding affinities and specificities have historically been 
measured by quantitative DNase I footprinting assays.
36 
As previously reported, however, cyclic 
polyamides have exceptionally high DNA binding affinities that exceed the detection limit of 
this experiment (i.e. Ka ≥ 2 x 1010 M-1).22,37,38 The DNA binding affinities of cyclic polyamides 
1–14 have been rank ordered by magnitude of DNA thermal stabilization (ΔTm), and compared 
to the corresponding hairpin polyamides 14–16. Spectroscopic measurements were performed on 
12-mer DNA duplexes with sequences 5’-CGATGTTCAAGC-3’, 5’-CGATGGTCAAGC-3’, 
and 5’-CGATCGTGAAGC-3’, each containing a match binding site for the corresponding 
polyamides.  
Consistent with the findings of Chenoweth et al, the ΔTm value for bis-amino cyclic 
polyamide 1 (ΔTm = 26.1oC) was calculated to be significantly higher than that of hairpin 
polyamide 15 (ΔTm = 22.0oC).22 So while 15 has an established binding affinity to the match 
androgen response element (ARE) half-site (5’-WGWWCW-3’) in the subnanomolar range, 
cyclic polyamide 1 provides even greater stabilization to such DNA duplexes. Mono-
unsubstituted cyclic polyamide 2 provides less DNA stabilization compared to 1 (ΔTm = 
20.4
o
C), which is likely due to the loss of a positive charge and thus the loss of favorable 
electrostatic interactions with the negatively-charged DNA backbone. Perhaps more surprising is 
the high ΔTm values retained by mono-protected cyclic polyamides 3 (ΔTm = 27.3oC) and 9 
(ΔTm = 28.0oC), each containing a lone free amino group and net +1 charge.  As shown in Fig. 
1, the benzoyl (Bz) group in 9 projects straight down the minor groove, avoiding unfavorable 
steric interactions with the groove wall, and may offer insight into the high degree of DNA 
stabilization by 3 and 9 comparable to the bis-amino cycle 1. Fluorescein-conjugate 12 (ΔTm = 
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21.8
o
C) has a DNA binding affinity lower than 3 and 9, perhaps due to increased steric clashes 
from the larger substitution group and unfavorable electrostatic interactions from the negatively-
charged fluorescein group, but still binds DNA at a similar level to 15.  
The magnitude of stabilization provided by cyclic polyamides 4–7, 10–11, and 13–14 
targeted to estrogen response element (ERE) half-sites (5’-WGGWCW-3’) follows a similar 
pattern to the aforementioned ARE-targeting series. Mono-unsubstituted cycle 5 (ΔTm = 18.6oC) 
stabilizes the duplex at a comparable level to hairpin polyamide 16 (ΔTm = 16.7oC), whereas 
bis-amino compound 4 (ΔTm = 23.2oC) has a higher ΔTm value. The mono-Cbz cycles 6 (ΔTm 
= 23.6
o
C) and 7 (ΔTm = 24.3oC), mono-Bz substituted 10 (ΔTm = 26.0oC) and 11 (ΔTm = 
25.1
o
C), and mono-fluorescein conjugates 13 (ΔTm = 22.2oC) and 14 (ΔTm = 21.0oC) each bind 
DNA similar to 4.  
Cyclic polyamide 8 (ΔTm = 13.4oC) binds the match 5’-WCGWGW-3’ sequence at an 
elevated level compared to hairpin 17 (ΔTm = 6.6oC), which may prove important towards 
targeting oncogenic transcription factors such as c-Myc that act through binding canonical E-Box 
(5’-CACGTG-3’) sequences.  
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C 
 
 
Figure 2.1 (Left) Stick model and (right) space-filling model of benzoyl substituted turn along 
the DNA minor groove from three different views. Based on published crystal structure by 
Chenoweth et al. (PDB ID: 3OMJ). 
 
 
57 
 
Table 2.3 Tm Values for polyamide library 
.  
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VI. Sulforhodamine B Cytotoxicity Assay for Compounds 1–11 
The cytotoxicity of compounds 1–11 were assessed in A549 human lung carcinoma and 
T47D human breast cancer cell lines (Tables 4 & 5).  The cyclic polyamides targeted to the 5’-
WGWWCW-3’ sequence generally exhibit a higher level of cytotoxicity than the 5’-
WGGWCW-3’series, which is consistent with the trends observed in the DNA thermal 
denaturation analysis and confocal microscopy studies. Detailed inspection of the IC50 values 
within the series of compounds and across the cell lines, however, offers some unanticipated 
insights into the different biological properties of these minor structural variants. 
Bis-amino cycle 1, which has previously been shown to be biologically active, did not 
display any significant level of cytotoxicity in either cell line (IC50 > 30 M). Mono-
unsubstituted compound 2 (IC50 = 4.9 M) and mono-Bz 9 (IC50 = 1.0 M) were comparably 
cytotoxic to hairpin polyamide 15 (IC50 = 3.1 M) in A549 cells, but an order of magnitude more 
cytotoxic (IC50 = 74 nM & 79 nM, respectively) than 15 (IC50 = 710 nM) in T47D cells. The 
mono-Cbz cycle 3 was consistently the most cytotoxic compound in both A549 (IC50 = 160 nM) 
and T47D (IC50 = 25 nM) cell lines. 
For the 5’-WGGWCW-3’ targeting polyamides, the only compound that exhibited an 
IC50 value lower than 30 M in A549 cells was the mono-Cbz compound 6 (IC50 = 1.9 M). In 
T47D cells, consistent with the 5’-WGWWCW-3’ series, bis-amino cycle 4 (IC50 > 30 M) was 
found to be not significantly cytotoxic and 6 (IC50 = 460 nM) was the most cytotoxic compound. 
Mono-unsubstituted cycle 5 (IC50 = 0.82 M) again shares a comparable level of cytotoxicity 
with the reference hairpin 16 (IC50 = 1.1 M), whereas mono-Bz compounds 10 (IC50 = 13.3 M) 
and 11 (IC50 = 7.5 M) are both an order of magnitude less cytotoxic.  
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Perhaps most interestingly, mono-Cbz compound 7 did not exhibit observable levels of 
cytotoxicity (IC50 > 30 M) in either A549 or T47D cells. Considering that 7 is a regioisomer of 
6, where the Cbz group is simply swapped onto the other turn, and that 7 only differs from 3 by a 
single –CH to -N substitution, it is rather surprising that 7 is more than 15- to 65- fold less 
cytotoxic than 6 and at least 180- to 1200- fold less cytotoxic than 3 in the two examined cell 
lines. Given the comparable DNA stabilization properties between 6 and 7, and their common 
core sequence, we would not have predicted this vast discrepancy in cytotoxicity.  
This study has demonstrated the large and somewhat unpredictable effects in biological 
activity induced by small structural variations of cyclic polyamides. Based on our preliminary 
work, the aggregation and pharmacokinetic properties of polyamides also vary greatly depending 
on structural modifications.
31–33
 All this combines to highlight the importance of a fast and 
reliable method to generate focused libraries of cyclic polyamides for future research. 
 
 
 
 
Table 2.4 SRB cytotoxicity data on compounds 1–3, 9, and 15, in A549 and T47D cells, 72 h 
incubation. 
 
 
 
60 
 
 
 
Table 2.5 SRB cytotoxicity data on compounds 4–7, 10–11, and 16, in A549 and T47D cells, 72 
h incubation. 
 
 
VII. Confocal Microscopy of Cyclic Polyamide-Fluorescein Conjugates 12–14 
To directly examine the cellular localization of cyclic polyamides, fluorescein conjugates 
12–14 were synthesized and visualized in living cells via confocal microscopy (Figs. 2 & 3). The 
selective conjugation of a single fluorescein molecule not only helped retain a free amino group 
for solubility purposes, but also allowed for the qualitative comparison of the two fluorescein 
conjugates 13 and 14 that share the same asymmetric polyamide core. 
In each of the cases examined, cyclic polyamides 12–14 appear to permeate through the 
cellular membrane and localize in the cell nucleus, which was confirmed by the co-localization 
with Hoechst 33258 DNA stain. For ease of qualitatively assessing compound uptake, all A549 
images were taken at a 660 fluorescence gain level, and all T47D images were taken at 600 
fluorescence gain.  Comparing Figures 2 and 3, the fluorescence levels of compounds 12–14 in 
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T47D cells are all significantly higher than in A549, which is only further amplified by this 
difference in gain levels.  
Compound 12 matched to the 5’-WGWWCW-3’ sequence exhibits the highest level of 
nuclear localization in both cell lines. Among the two 5’-WGGWCW-3’ targeting cycles, 
polyamide 14 qualitatively appears to have a relatively higher fluorescence signal in the cell 
nuclei in both A549 and T47D cells. This may help explain the cytotoxicity data reported above, 
where compounds 6 and 11 with Cbz and Bz substitutions on the same side as the fluorescein in 
14 consistently display larger biological effects than 7 and 10 that are more structurally similar to 
cyclic polyamide 13.  
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Figure 2.2 Confocal microscopy of cyclic polyamide-fluorescein conjugates 12 (top), 13 
(middle), and 14 (bottom) in A549 cells. In order to confirm nuclear localization, the 
fluorescence panel (left) was compared with Hoechst 33258 staining (middle) and overlay 
(right).  
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Figure 2.3 Confocal microscopy of cyclic polyamide-fluorescein conjugates 12 (top), 13 
(middle), and 14 (bottom) in T47D cells. In order to confirm nuclear localization, the 
fluorescence panel (left) was compared with Hoechst 33258 staining (middle) and overlay 
(right). 
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2.3. Conclusion 
We have described a modular solid-phase synthesis method, which, when combined with 
an established DPPA-mediated macrocyclization step, afforded cyclic polyamides in a high-
yielding and time-efficient manner. Using this method, we have overcome previous limitations 
and synthesized both cyclic and hairpin polyamides that start with an imidazole unit. The binding 
affinities of all synthesized cycles have been assessed by DNA thermal denaturation assays and 
compare favorably to hairpin polyamides that bind their match DNA sequences at subnanomolar 
concentrations. Furthermore, the protection strategy of our method allows for selective 
modification of the GABA turn units, which we have used to rapidly generate a focused library 
of compounds. The cytotoxicity and uptake analysis of the cyclic polyamides revealed 
unexpected properties that further highlight the need for an efficient method to synthesize 
structural variants of cyclic polyamides for future studies.   
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2.4 Materials and Methods 
Materials 
2-Chlorotrityl chloride (2-Cl-Trt-Cl) resin was purchased from Bachem. FmocPyOH and 
FmocImOH monomers were purchased from Wako. PyBOP was purchased from NovaBioChem. 
Boc--Dab(Fmoc)-OH was purchased from Peptides International. All DNA oligomers were 
purchased HPLC purified from Integrated DNA Technologies. Cell culture media was purchased 
from Gibco. Fetal bovine serum was purchased from Omega Scientific.  
 
Methods 
Microwave-assisted coupling reactions were conducted on a Biotage Initiatior Eight 
synthesizer. Polyamide concentrations were measured in 20% MeCN in 0.1% (v/v) aqueous TFA 
using an approximated extinction coefficient of 69 200 M
-1
 cm
-1
 at λmax near 310 nm, unless 
otherwise specified.
32, 36 
 
I. Monomer Loading onto 2-Cl-Trt Resin 
Prior to manual microwave-assisted synthesis, 2-Cl-Trt-Cl resin (1.0 g, 1.59 mmol/g),  
was first loaded by mixing with 576 mg (1.59 mmol, 1 eq.) of FmocPyOH monomer, followed 
by addition of 6 mL dimethylformamide (DMF) and 1.38 mL diisopropylethylamine (DIEA) 
(7.59 mmol, 5 eq.). The suspended mixture was stirred for 18 h, then capped by addition of 1 mL 
methanol (MeOH) and stirred for 1 h.  The orange-colored, loaded resin was then collected on a 
fritted peptide synthesis vessel, washed with DMF (2x), MeOH (2x), DMF (2x), MeOH (2x), 
and diethylether (Et2O). [Owing to the sensitivity of the 2-Cl-Trt resin towards 
hydrolysis/methanolysis, this final Et2O wash was found to be essential and all loaded resin was 
sealed and stored at -20 
o
C.] The loading efficiency was quantitated via the Fmoc test, and 
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confirmed by measuring the mass of the dried resin. Typical monomer loading was calculated to 
be 0.4–0.8 mmol/g. 
 
II. Microwave-Assisted Solid-Phase Synthesis (18–24) 
All solid-phase polyamide coupling reactions were performed manually on a Biotage 
Initiator Eight microwave synthesizer on a 200–500 mg scale of loaded resin. Prior to each 
monomer coupling reaction, the N-terminal Fmoc group was first removed in a piperidine 
solution. The Fmoc deprotections were performed in a fritted peptide synthesis vessel at room 
temperature, and the specific conditions for each N-terminal monomer are as follows: 
N-Fmoc-Pyrrole / Imidazole: (a) swell resin in DCM; (b) wash with DMF; (c) add 50% 
piperidine in DMF; (d) shake suspension for 10 min; (e) wash with DMF; (f) repeat steps a-e 
twice.  
N-Fmoc-GABA / -Alanine: (a) swell resin in DCM; (b) wash with DMF; (c) add 50% 
piperidine in DMF; (d) shake suspension for 5 min; (e) wash with DMF; (f) repeat steps a-e 
once. 
Following Fmoc removal, the resin was de-swelled in MeOH, washed with Et2O, dried in 
vacuo, and transferred to a microwave synthesis vessel as a dry powder. The corresponding 
monomer acid (3 eq.) was activated with PyBOP (3 eq.) and DIEA (6 eq.) in DMF (0.3 M 
concentration of monomer), and added to the resin.  The coupling reactions were then set up in 
the microwave reactor at 50 
o
C for the time durations described in Table 1. After the listed 
microwave-assisted coupling times, the reaction mixture was filtered into a peptide synthesis 
vessel, and the collected resin was washed with DMF (3x), MeOH (3x), Et2O, and dried in 
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vacuo. To ensure completion of each deprotection and coupling step, analytical HPLC spectra 
were taken by cleaving a small resin sample in 30% hexafluoroisopropanol (HFIP) in DCM.  
The polyamide core was synthesized on 2-Cl-Trt resin in an iterative manner by repeating 
the deprotection-coupling procedures described above using the corresponding monomeric units. 
Upon completion of the sequence, 100–200 mg of the resin was suspended in 1 mL 30% HFIP in 
DCM and stirred for 1 h to yield the crude N-terminal Fmoc-protected polyamide intermediate. 
The reaction mixture was then run through a cotton filter to remove the resin, and the filtrate was 
concentrated in vacuo. The residual oil was resuspended in 5 mL of a 1:1 MeOH:DCM mixture, 
and reconcentrated in vacuo to give an off-white / beige solid. To remove the N-terminal Fmoc 
group, the solid was redissolved in 800 L DMF, followed by addition of 200 L piperidine, and 
the solution was stirred for 30 min. Upon confirmation of complete deprotection by analytical 
HPLC, the solution was added to 4 mL 30% MeCN in 0.1% aqueous TFA. The precipitated 9-
methylenefluorene side product was then removed by centrifugation, and washed twice with 2 
mL 30% MeCN in 0.1% aqueous TFA. The combined aqueous solution was purified by reverse-
phase HPLC and lyophilized to dryness to yield pre-cyclic polyamide intermediates 18-24.  All 
dried samples of 18–24 were stored at -20 oC prior to DPPA-mediated macrocyclization.  
 
Synthetic yields and MALDI-TOF characterization data for 18–24 are summarized below: 
(18): 12.6 mol recovered (38.0 mol theoretical, 33% yield). MALDI-TOF [M + H]+ calcd for 
C70H77N22O15
+
 = 1465.4, observed = 1465.9. 
(19):  15.2 mol recovered (38.0 mol theoretical, 40% yield). MALDI-TOF [M + H]+ calcd for 
C62H70N21O13
+
 = 1316.5, observed = 1316.9.  
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(20):  12.8 mol recovered (38 mol theoretical, 34% yield). MALDI-TOF [M + Na]+ calcd for 
C67H79N22NaO15
+
 = 1453.6, observed = 1453.9.  
(21):  15.1 mol recovered (49 mol theoretical, 31% yield). MALDI-TOF [M + H]+ calcd for 
C69H76N23O15
+
 = 1466.5, observed = 1466.9.  
(22):  17.2 mol recovered (51 mol theoretical, 34% yield). MALDI-TOF [M + H]+ calcd for 
C61H69N22O13
+
 = 1317.5, observed = 1317.2.  
(23):  16.2 mol recovered (51 mol theoretical, 32% yield). MALDI-TOF [M + Na]+ calcd for 
C66H77N23NaO15
+
 = 1454.5, observed = 1455.0. 
(24):  8.2 mol recovered (25 mol theoretical, 33% yield). MALDI-TOF [M + Na]+ calcd for 
C66H78N23NaO15
+
 = 1454.5, observed = 1454.9. 
 
III. DPPA-mediated Macrocyclization (1-7)  
The macrocyclization reactions were run on a 2 mol to 16 mol scale. Intermediates 18-
24 were first dissolved in DMF (0.25 mM) in a round-bottom flask equipped with a magnetic stir 
bar, followed by addition of DIEA (200 eq.), and purged with argon for 15 min. 
Diphenylphosporyl azide (DPPA) (50 eq.) was then added to the reaction mixture in a dropwise 
manner, while rapidly stirring. Upon full addition of the DPPA, the solution was allowed to react 
and stirred at room temperature for 16–20 h. After confirmation of reaction completion by 
analytical HPLC, the reaction mixture was concentrated in vacuo, and the resulting oil residue 
was dissolved in 3 mL MeCN and transferred to a 15 mL Falcon Tube. The MeCN was then 
removed with air flow and 3 mL 0.1% aqueous TFA was added to the remaining oil layer to 
yield an off-white suspension, which was isolated via centrifugation and lyophilized to dryness.  
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For reactions starting with 18, 19, 21, and 22, the lyophilized residue was submitted to 1 
mL 10% trifluoromethanesulfonic acid (TFMSA) in TFA, stirred for 5 min, frozen in LN2, and 
thawed by layering 1 mL DMF. For reactions starting with 20, 23, and 24, the lyophilized 
residue was submitted to 1 mL neat TFA, stirred for 15 min, frozen in LN2, and thawed by 
layering 1 mL DMF. All the thawed solutions were then diluted with 6 mL 0.1% aqueous TFA, 
purified by reverse-phase HPLC and lyophilized to dryness to yield cyclic polyamides 1–7.  
 
Synthetic yields and MALDI-TOF characterization data for 1–7 are summarized below: 
(1):  4.5 mol recovered (12.9 mol theoretical, 35% yield). MALDI-TOF [M + H]+ calcd for 
C54H63N22O10
+
 = 1179.5, observed = 1179.9. 
(2):  0.84 mol recovered (2.0 mol theoretical, 42% yield). MALDI-TOF [M + H]+ calcd for 
C54H62N21O10
+
 = 1164.5, observed = 1164.6. 
(3):  3.2 mol recovered (6.7 mol theoretical, 47% yield). MALDI-TOF [M + H]+ calcd for 
C62H69N22O12
+
 = 1313.6, observed = 1314.0. 
(4):  3.1 mol recovered (8.0 mol theoretical, 39% yield). MALDI-TOF [M + H]+ calcd for 
C53H62N23O10
+
 = 1180.5, observed = 1180.9. 
(5):  0.96 mol recovered (2.0 mol theoretical, 48% yield). MALDI-TOF [M + H]+ calcd for 
C53H61N22O10
+
 = 1165.5, observed = 1165.5. 
(6):  3.7 mol recovered (10.0 mol theoretical, 37% yield). MALDI-TOF [M + H]+ calcd for 
C61H68N23O12
+
 = 1314.5, observed = 1314.5. 
(7):  2.2 mol recovered (5.7 mol theoretical, 38% yield). MALDI-TOF [M + H]+ calcd for 
C61H68N23O12
+
 = 1314.5, observed = 1314.8. 
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IV. Selective Conjugation of Benzoic Acid Derivatives (9–11)  
A solution of benzoic acid (3.0 mg, 0.025 mmol, 25 eq.) and PyBOP (13 mg, 0.025 
mmol, 25 eq.) in DMF (0.5 mL) and DIEA (44 L, 0.25 mmol, 250 eq.) was stirred at room 
temperature for 10 min. The activated solution was then added to 3 (1.0 mol) and stirred for 3 
h. After confirmation of complete reaction by analytical HPLC, 12 mL cold Et2O was added to 
the reaction mixture and cooled at -20
o
C for 16 h. The precipitate was then isolated by 
centrifugation and allowed to air dry. The resulting residue was submitted to 1mL 10% 
trifluoromethanesulfonic acid (TFMSA) in TFA, stirred for 5 min, frozen in LN2, and thawed by 
layering 1 mL DMF. The thawed solution was then diluted with 6 mL 0.1% aqueous TFA, 
purified by reverse-phase HPLC and lyophilized to dryness to yield cyclic polyamides 9 (684 
nmol, 68% yield).  Using the same procedure described above, starting with 6 (1.60 mol) and 7 
(750 nmol), yielded mono-benzoyl substituted cyclic polyamides 10 (1.05 mol, 67% yield) and 
11 (367 nmol, 49% yield), respectively.  
(9): MALDI-TOF [M + H]
+ 
calcd for C61H67N22O11
+
 = 1283.5, observed = 1284.1. 
(10): MALDI-TOF [M + H]
+ 
calcd for C60H66N23O11
+
 = 1284.5, observed = 1284.5. 
(11): MALDI-TOF [M + H]
+ 
calcd for C60H66N23O11
+
 = 1284.5, observed = 1284.9. 
 
V. Synthesis of Cyclic Polyamide-Fluorescein Conjugates (12–14) 
A solution of fluorescein isothiocyanate (FITC) (2.7 mg, 7.0 mol, 25 eq.) in DMF (0.2 
mL) and DIEA (12 L, 0.07 mmol, 250 eq.) was added to 3 (0.28 mol) and stirred for 2 h. After 
confirmation of complete reaction by analytical HPLC, 12 mL cold Et2O was added to the 
reaction mixture and cooled at -20 
o
C for 16 h. The precipitate was then isolated by 
centrifugation and allowed to air dry. The resulting residue was submitted to 1 mL 10% 
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trifluoromethanesulfonic acid (TFMSA) in TFA, stirred for 5 min, frozen in LN2, and thawed by 
layering 1 mL DMF. The thawed solution was then diluted with 6 mL 0.1% aqueous TFA, 
purified by reverse-phase HPLC and lyophilized to dryness to yield cyclic polyamide 12 (65 
nmol, 23% yield). Using the same procedure described above, starting with 6 (0.40 mol) and 7 
(0.40 mol), yielded cyclic polyamide-fluorescein conjugated 13 (345 nmol, 86% yield) and 14 
(118 nmol, 29% yield), respectively. 
(12): ESI-MS [M + H]
+ 
calcd for C75H74N23O15S
+
 = 1568.6, observed = 1568.3. 
(13): ESI-MS [M + H]
+ 
calcd for C74H73N24O15S
+
 =  1569.5, observed = 1569.2. 
(14): ESI-MS [M + H]
+ 
calcd for C74H73N24O15S
+
 = 1569.5, observed = 1569.3. 
 
VI. Synthesis of Cyclic Polyamide Targeted to 5’-WCGWGW-3’ Sequence (8) 
2-Cl-Trt-Cl resin (200 mg, 1.59 mmol/g) was first loaded with FmocPyImOH dimer (96 
mg, 0.20 mmol), which was obtained from published procedures.
13
 Experimental details were 
analogous to the monomer loading protocol reported above. The obtained Fmoc-Py-Im-(2-Cl-
Trt) resin (265 mg, 0.59 mmol/g) was subjected to the previously described microwave-assisted 
solid-phase synthesis conditions to build the corresponding polyamide sequence. A quarter of the 
resin (0.15 mol theoretical) was then cleaved and purified by reverse-phase HPLC to yield pre-
cyclic polyamide intermediate 25 as an off-white powder (13.3 mol, 34% yield). The isolated 
25 (2.0 mol) was subjected to DPPA-mediated macrocyclization conditions analogous to that 
for compounds 1–7, with the Cbz groups removed with 10% TFMSA in TFA, and purified by 
reverse-phase HPLC to afford cyclic polyamide 8 (773 nmol, 39% yield). 
(25): MALDI-TOF [M – CO2 + H]
+ 
calcd for C65H675N22O13
+
 = 1371.6, observed = 1371.7. 
(8): MALDI-TOF [M + H]
+ 
calcd for C61H67N22O11
+
 = 1129.5, observed = 1130.0 
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VII. Synthesis of Hairpin Polyamide Targeted to 5’-WCGWGW-3’ Sequence (17) 
Fmoc-Py-Im-(2-Cl-Trt) resin, obtained via the same procedure as for 8, was subjected to 
the previously described microwave-assisted solid-phase synthesis conditions to build the 
corresponding polyamide sequence with an N-terminal PyImOH cap. The resin (70 mg, 0.039 
mmol) was then suspended in 2 mL 30% HFIP in DCM, stirred for 1 h, filtered, washed, and 
concentrated to afford the crude C-terminal free acid. The residue was then dissolved in DMF 
(1.8 mL) and added dropwise to a pre-activated solution of 3,3’-diamino-N-methyldipropylamine 
(252 L, 1.56 mmol, 40 eq.) and PyBOP (40 mg, 0.078 mmol, 2 eq.) in DMF (6.0 mL). After  
stirring for 1 h and confirmation of complete conjugation by HPLC, the crude product was 
isolated by Et2O precipitation, air dried, redissolved in 8 mL 15% AcN : 0.1% aqueous TFA, and 
purified by reverse-phase HPLC to yield polyamide intermediate 26 as an off-white powder 
(11.8 mol, 30% yield).  
The isolated 26 (3.1 mol) was dissolved in DMF (200 L) and added dropwise to a pre-
activated solution of isophthalic acid (12 mg, 0.072 mmol) and PyBOP (5 mg, 9mol) in DMF 
(800 L) and DIEA (13 L). After stirring for 1 h and confirmation of complete conjuation by 
HPLC, the reaction mixture was then precipitated in Et2O, isolated by centrifugation, and air 
dried. The remaining residue was then subjected to 500 L neat TFA, stirred for 15 min, frozen 
in LN2, thawed by addition of 1 mL DMF, diluted with 6 mL 0.1% aqueous TFA, and purified 
by reverse-phase HPLC to afford cyclic polyamide 8 (3.1 nmol, 86% yield). [Note: Extinction 
coefficient for compounds 26 and 17 were established as 40,000 M
-1
 cm
-1
 at λmax = 302 nm.] 
(26): MALDI-TOF [M + H]
+ 
calcd for C58H79N22O11
+
 = 1259.6, observed = 1260.1. 
(17): MALDI-TOF [M + H]
+ 
calcd for C61H75N22O12
+
 = 1307.6, observed = 1307.8. 
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VIII. Thermal Denaturation Analysis 
Melting temperature analysis was performed on a Varian Cary 100 spectrophotometer 
equipped with a thermo-controlled cell holder possessing a cell path length of 1 cm. A degassed 
aqueous solution of 10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2 at 
pH 7.0 was used as analysis buffer. DNA duplexes and polyamides were mixed in 1:1 
stoichiometry to a final concentration of 2 μM for each experiment. Prior to analysis, samples 
were heated to 95 °C and cooled to a starting temperature of 25 °C with a heating rate of 5 °C / 
min for each ramp. Denaturation profiles were recorded at λ = 260 nm from 25 to 95 °C with a 
heating rate of 0.5 °C / min. The reported melting temperatures were defined as the maximum of 
the first derivative of the denaturation profile. 
 
IX. Cell Culture 
Cell lines were cultured at 37 °C under 5% CO2 using standard cell culture and sterile 
techniques. Cell medium was supplemented with 10% fetal bovine serum. Ham's F-12K 
(Kaighn's) medium was used for A549 cells, and RPMI 1640 was used for T47D cells. 
 
X. Confocal Microscopy  
For each experiment, cells were plated in 200 L of the proper medium onto glass-
bottom cell culture plates at a density of 1 × 105 (A549) cells/ mL, or 1.5 × 105 cells/ mL (T47D). 
Cells were grown for 24 h, and media was replaced with fresh media containing polyamide to 
give a final DMSO concentration of 0.1%. Next, cells were incubated for 16 h, followed by 
removal of media, washing, and addition of fresh media. Hoechst 33258 was added 2 h prior to 
imaging. Imaging was performed at the Caltech Beckman Imaging Center using a Zeiss LSM 
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510 Meta NLO 2-photon inverted laser scanning microscope equipped with a 40x oil-immersion 
objective lens. Polyamide–fluorescein conjugates 12–14 were imaged in multi-track mode using 
488 nm laser excitation at 15% output with a pinhole of 375 µm and a standard fluorescein filter 
set. Hoechst was imaged using 800 nm two-photon excitation with an HFT KP680 dichroic and a 
390- to 465-nm bandpass filter with a fully open pinhole. All images were analyzed using Zeiss 
LSM Zen software. 
 
XI. Sulforhodamine B Cytotoxicity  
For cytotoxicity assays, cell lines were plated in 96-well cell culture plates in 100 L 
media at a density of 1 × 104 cells/mL (A549), or 5 × 104 cells/mL (T47D). IC50 values were 
determined using the sulforhodamine B (SRB) colorimetric assay as previously described.
39 
Cells 
were grown for 24 h, before polyamides in 100 L media were added in serial dilution, in 
quadruplicate for each concentration. After incubation for 72 h, cell media was replaced with 100 
L fresh media, and cells were allowed to recover for an additional 24 h. Cells were then fixed 
by adding 100 L of 10% trichloroacetic acid directly to each well and stored at 4°C for 1 h, 
before being washed, dried, stained with 100 L 0.057% SRB solution per well for 30 min, and 
washed and dried again as described. After solubilizing the bound dye with 200 L of 10 mM 
Tris (pH 10.5) per well, absorbance at 490 nm was measured on a PerkinElmer Victor microplate 
reader. The data are charted as a percentage of untreated controls, corrected for background 
absorbance. IC50 is defined as the concentration that inhibits 50% of control cell growth. These 
values were determined by non-linear least-squares regression fit to Y = A + (B − A)/(1+10^((Log 
EC50 − X) × H)), where A = max., B = min. and H = Hill Slope. All calculations were performed 
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using Prism 4 (GraphPad) software. Stated IC50 values represent the mean and standard deviation 
of three independent biological replicates. 
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2.7 Experimental Data 
 
Figure 2.4 HPLC spectrum of 18 and 1. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.5 HPLC spectrum of 19 and 2. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.6 HPLC spectrum of 20 and 3. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.7 HPLC spectrum of 21 and 4. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.8 HPLC spectrum of 22 and 5. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.9 HPLC spectrum of 23 and 6. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.10 HPLC spectrum of 24 and 7. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.11 HPLC spectrum of 25 and 8. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.12 HPLC spectrum of 26 and 17. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.13 HPLC spectrum of 9 and 12. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.14 HPLC spectrum of 10 and 13. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
90 
 
 
Figure 2.15 HPLC spectrum of 11 and 14. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.16 HPLC spectrum of 15 and 16. Reverse-phase HPLC taken on Beckman Gold 
instrument equipped with a Phenomenex Gemini analytical column (250 × 4.6 mm, 5 μm) and a 
diode array detector, and the mobile phase consisted of a gradient of acetonitrile (MeCN) in 
0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Figure 2.17 Confocal microscopy analysis of 12–14 in A549 cells. 
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Figure 2.18 Confocal microscopy analysis of 12–14 in T47D cells. 
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Figure 2.19 The cytotoxicity of compound S1 in A549 cells was examined using Sulforhodamine 
B assay described in the text. The IC50 was determined to be 0.003M ± 0.002M. 
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Chapter 3 
 
 
 
 
 
 
DNA Sequence Selectivity of Hairpin Polyamide Turn Units 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text of this chapter was taken in part from a manuscript co-authored with Michelle E. Farkas, 
Christian Dose, and Peter B. Dervan (California Institute of Technology). 
 
 
 
 
Farkas, M.E.; Li, B.C.; Dose, D.; Dervan, P.B. “DNA Sequence Selectivity of Hairpin Polyamide Turn 
Units” Bioorg. Med. Chem. Lett. 2009, 19, 3919–3923. 
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Abstract 
 A class of hairpin polyamides linked by 3,4-diaminobutyric acid, resulting in a β-amine 
residue at the turn unit, showed improved binding affinities relative to their α-amino-γ-turn analogs for 
particular sequences.  We incorporated β-amino-γ-turns in six-ring polyamides and determined 
whether there are any sequence preferences under the turn unit by quantitative footprinting titrations. 
Although there was an energetic penalty for G•C and C•G base pairs, we found little preference for 
T•A over A•T at the β-amino-γ-turn position. Fluorine and hydroxyl substituted α-amino-γ-turns were 
synthesized for comparison. Their binding affinities and specificities in the context of six-ring 
polyamides demonstrated overall diminished affinity and no additional specificity at the turn position. 
We anticipate that this study will be a baseline for further investigation of the turn subunit as a 
recognition element for the DNA minor groove. 
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3.1 Introduction  
Hairpin pyrrole-imidazole (Py-Im) polyamides are a class of programmable synthetic ligands 
able to bind a broad repertoire of  DNA sequences with affinities and specificities comparable to those 
of DNA-binding proteins.
1,2
 They have been shown to localize to the nuclei of living cells 
3, 4
 and 
regulate endogenous gene expression by interfering with transcription factor/DNA interfaces.
5–10
  
Discrimination of the four Watson-Crick base pairs is dependent upon Py-Im ring pairings in the minor 
groove.  Pairing rules have been established whereby N-methyl imidazole/N-methylpyrrole (Im/Py) 
pairs target G•C, the reverse (Py/Im) target C•G, and Py/Py pairs target A•T and T•A.11–13  
 
 
Figure 3.1 Schematic diagram of six-ring hairpin polyamide (ImImPy-turn-PyPyPy) targeting the 
DNA sequence 5’-WWGGWW-3’. Dashed lines indicate hydrogen bonds between the polyamide and 
DNA base pairs. 
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 The turn unit in the hairpin is a recognition element, favoring T•A / A•T over G•C / C•G.14 
There is an energetic penalty for unfavorable steric interaction with the exocyclic amine present at the 
edge of the G•C base pair (Fig. 1). The question arises whether discrimination between T•A and A•T 
with the turn unit can be achieved. Previous efforts toward the improvement of hairpin binding affinity 
have involved modifications of the turn unit.  Early studies showed the optimal length of the turn 
element to be three methylene units, resulting in the use of γ-aminobutyric acid (γ-turn).15  
Modification of the α-position of the parent γ-turn with (R)-2,4-diaminobutyric acid (α-amino-γ-turn) 
results in an approximately fifteen-fold increase in DNA-binding affinity.
16
  In contrast, hairpins 
containing the opposite enantiomer, (S)-α-amino-γ-turn, bind DNA with diminished affinities likely 
due to a steric clash of the amine with the wall of the minor groove.  Polyamides containing α-
hydroxy-γ-turns17 and α-diaminobutyric acid18 turns have been reported to impart additional elements 
of specificity, but with the cost of diminished binding affinities.  
 In a formal sense, a DNA minor groove binding hairpin Py-Im polyamide is an early example 
of a class of oligomers encoded by the order of monomer units that fold to a desired shape with a 
specific function, referred to as “foldamers.”19–21 The ring order of Py-Im polyamides codes in a 
programmable manner for a specific, contiguous sequence of Watson-Crick base pairs. The turn unit is 
both a shape element as well as a DNA recognition element, allowing the molecule to fold in a U-
conformation. The turn unit deserves more attention and this paper represents an effort to create a 
baseline for the field.  
 Recently, we introduced a new class of hairpin polyamides linked by 3,4-diaminobutyric acid, 
resulting in a β-amino-γ-turn.22 These molecules showed improved binding affinities relative to their α-
amino-γ-turn analogs for A/T-rich sequences.  Additionally, polyamides containing the β-amino-γ-turn 
were found to have improved tolerance for synthetic modification at the amine position presumably 
due to their more central location on the floor of the minor groove.  Due to limitations of quantitative 
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DNase I footprinting titrations
23–25
 for compounds where Ka ≥ 10
10
 M
-1
, relative binding affinities for 
high affinity molecules are compared by using their thermal stabilization of DNA duplexes.  It has 
been shown previously that increases in melting temperatures (ΔTm) of DNA duplexes bound by 
hairpin polyamides correlate with DNA-binding affinity.
26, 27
 
 We report herein a comparison of the sequence specificities of hairpin Py-Im polyamides 
containing the α-amino-γ-turn and the β-amino-γ-turn.  Additionally, we have synthesized both 
hydroxyl and fluoro-substituted α-amino-γ-turns and determined their affinities and specificities in 
polyamides with analogous core ring pairs. By employing six-ring polyamides, which have lower 
binding affinities compared to eight-ring polyamides,
28
 we are able to determine reliable equilibrium 
association constants (Ka) via quantitative DNase I footprinting titrations, and compare them with 
DNA duplex thermal stabilizations.  
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3.2 Results and Discussion 
I. Polyamide synthesis 
Six-ring hairpin polyamides (ImImPy-turn-PyPyPy) targeting the DNA sequence 5’-
WWGGWW-3’ were synthesized by solid-phase methods on PAM resin (Fig. 3.2).22, 29 In addition to 
the parent molecule containing an unsubstituted γ-aminobutyric acid hairpin (1), oligomers containing 
an amine moiety in the α and β turn positions (2R, 4R, 4S) and two polyamides with acetylated amines 
(3R, 5R) were also synthesized.  The acetylated, or capped, molecules were used to determine 
tolerance for modifications at the turn. Acetylated turn units have been shown to improve nuclear 
uptake of polyamides.
4
  
 
Figure 3.2 Chemical and ball-and-stick structures of polyamides containing free and acetylated 
amines. Ball-and-stick symbols are defined as follows: pyrrole is denoted by an open circle, imidazole 
is denoted by a filled circle, and β-alanine is denoted by a diamond shape. 
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II. Thermal stabilization of DNA duplexes.  
Spectroscopic analyses were performed on the 11mer DNA duplex shown in Table 3.1.
22
  All 
hairpins analyzed provided an increase in melting temperature, confirming the formation of 
DNA/polyamide complexes.  The ΔTm values obtained for polyamides containing a free amine were 
within error of each other.  However, acetylated polyamide 3R (α-amino turn) showed a greater 
decrease in affinity than 5R (β-amino-γ-turn).  As had been demonstrated with eight-ring hairpin 
molecules,
22
 improvements in binding affinities for β- over α-amino-γ-turn six-ring polyamides are 
more pronounced with decreasing imidazole content (Fig. S3.10, Table 3.7).  
 
 
Table 3.1 Melting temperatures of DNA/polyamide complexes for 1, 2R, 4R, 4S, 3R, and 5R. All 
values are derived from at least three melting temperature experiments, with standard deviations 
indicated in parentheses. ΔTm values are given as Tm (DNA/polyamide) − Tm (DNA). 
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III. DNA binding affinity and sequence selectivity 
The plasmid pCDMF6 was prepared to characterize polyamides targeting the sequence 5’-
WGGWW-3’ (Fig. 3.3).  The designed insert contains four binding sites, varying the nucleotide base 
pair present under the turn unit.   
 
 
Figure 3.3 Illustration of the EcoRI/PvuII restriction fragment derived from plasmid pCDMF6, used to 
characterize polyamides. The designed polyamide binding sites are indicated by boxes; single base-
pair mismatches are indicated by shaded regions. 
 
 
 
Quantitative DNase I footprinting titrations were performed with the polyamides in order to 
measure their binding site affinities and specificities, as previously described.
25
 As expected, the parent 
hairpin containing the γ-turn retained the lowest binding affinity, while experiments for 2R, 4R, and 
4S (Fig. 3.4, Table 3.2) corroborated the similar ΔTm values obtained for duplex stabilization.  None of 
these molecules bound the G•C base pair, and binding to C•G was greatly diminished.  Polyamide 4R 
revealed only a two-fold specificity for T•A over A•T (Table 3.3).  Study of an additional polyamide 
series revealed similar trends (Fig. 3.5, Table 3.8).  Analysis of polyamides 3R and 5R (Fig. 3.5, Table 
3.2) revealed a greater decrease in binding affinities for the α-amino-γ-turn molecule than the β.  
Between 2R and 3R there is a five-fold decrease over T•A, and an eight-fold decrease over A•T.  For 
β-amino-γ-turn polyamides 4R and 5R, there are 1.7- and 3.2- fold decreases for T•A and A•T, 
respectively. 5R shows three-fold preference for binding T•A versus A•T (Table 3.3). 
 
 
103 
 
 
 
 
Figure 3.4 Quantitative DNase I footprinting titration experiments for polyamides 1, 2R, 4R, and 4S 
(left to right) on the 5’ end labeled PCR product of plasmid pCDMF6: lanes 1–11, 100 nM, 30 nM, 10 
nM, 3 nM, 1 nM, 300 pM, 100 pM, 30 pM, 10 pM, 3 pM, and 1 pM polyamide, respectively; lane 12, 
DNase I standard; lane 13, intact DNA; lane 14, A reaction; lane 15, G reaction.  Respective isotherms 
are shown below. 
 
 
Table 3.2 Binding affinities (M
-1
) for polyamides for 1, 2R, 4R, 4S, 3R, and 5R. Equilibrium 
association constants are reported as mean values from three DNase I footprinting titration 
experiments. Standard deviations are shown in parentheses. 
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Figure 3.5 (left) Quantitative DNase I footprinting titration experiments for polyamides 3R (left) and 
5R (right) on the 5’ end labeled PCR product of plasmid pCDMF6: lanes 1–11, 100 nM, 30 nM, 10 
nM, 3 nM, 1 nM, 300 pM, 100 pM, 30 pM, 10 pM, 3 pM, and 1 pM polyamide, respectively; lane 12, 
DNase I standard; lane 13, intact DNA; lane 14, A reaction; lane 15, G reaction.  Respective isotherms 
are shown below. 
 
Table 3.3 (right) Relative binding affinities for polyamides 1, 2R, 4R, 4S, 3R, and 5R. Relative 
binding affinities are reported as ratios of binding affinities (Ka) as determined by DNase I 
footprinting titration experiments for polyamides targeting 5’-WGGWW-3’. Sites containing G•C at 
the hairpin position have relative affinities < 0.01 (not shown). 
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IV. Fluoro and Hydroxyl Substituted Turn Units  
Fluorine and hydroxyl substituted hairpin turns were synthesized (Scheme 3.1 and 3.2) and 
incorporated in six-ring hairpin polyamides targeting the DNA sequence 5’-WWGGWW-3’ (Fig. 
3.6).
30, 31
 Polyamides were synthesized on PAM resin using standard solid-phase methods. 
 
Scheme 3.1 Synthesis of -fluoro GABA turns 18 and 22 
 
 
 
1
Reagents and conditions: (a) phthalic anhydride, 140 
o
C; (b) 2M HCl in Et2O, MeOH; (c) DAST, pyridine, DCM; (d) 6M 
HCl (aq); (e) Boc2O, NaHCO3, THF, H2O; (f) p-NO2-PhCO2H, PPh3, DIAD, THF; (g) Et3N, MeOH; (h) DAST, pyridine, 
DCM; (i) 6M HCl (aq); (j) Boc2O, NaHCO3, THF, H2O. 
 
 
 
Scheme 3.2 Synthesis of -hydroxyl GABA turns 23 and 26 
 
 
 
 
1
Reagents and conditions: (a) Boc2O, NaHCO3, dioxane, H2O; (b) CH3I, K2CO3, DMF; (c) p-NO2-PhCO2H, PPh3, DIAD, 
THF; (d) Et3N, MeOH; (e) NaOH (aq), MeOH. 
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Figure 3.6 Chemical and ball-and-stick structures of polyamides 6R, 7R, 6S, and 7S containing fluoro 
and hydroxyl substituted hairpin turns. Ball-and-stick symbols are defined as follows: pyrrole is 
denoted by an open circle, imidazole is denoted by a filled circle, and β-alanine is denoted by a 
diamond shape. 
 
 
 
Table 3.4 Melting temperatures of DNA/polyamide complexes for 6R, 7R, 6S, and 7S. All values are 
derived from at least three melting temperature experiments, with standard deviations indicated in 
parentheses. ΔTm values are given as Tm (DNA/polyamide) − Tm (DNA). 
 
 Thermal stabilization analysis of the polyamides on an 11mer DNA duplex revealed that fluoro 
and hydroxyl substituted hairpins resulted in lower stabilizations than the corresponding amine-
substituted and acetylated polyamides (Table 3.4). DNase I footprinting titrations on the plasmid 
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pCDMF6 (Fig. 3.3, Fig. 3.7) showed that both enantiomers of the hydroxyl and fluoro-hairpin turns 
resulted in decreased polyamide binding affinities relative to their amine substituted counterparts 
(Table 3.5). Additionally, none of these subunits resulted in increased elements of specificity at the 
turn position of the molecule (Table 3.6).   
 
 
 
Figure 3.7 Quantitative DNase I footprinting titration experiments for polyamides 6R, 7R, 6S, and 7S 
(left to right) on the 5’ end labeled PCR product of plasmid pCDMF6. For 6R: lanes 1–11, 100 nM, 30 
nM, 10 nM, 3 nM, 1 nM, 300 pm, 100 pM, 30 pM, 10 pM, 3 pM, and 1 pM polyamide, respectively; 
lane 12, DNase I standard; lane 13, intact DNA; lane 14, A reaction; lane 15, G reaction. Polyamides 
7R, 6S, and 7S: lanes 1-11, 10 μM, 3 μM, 1 μM, 300 nM, 100 nM, 30 nM, 10 nM, 3 nM, 1 nM, 300 
pM, and 100 pM polyamide, respectively; lane 12, DNase I standard; lane 13, intact DNA; lane 14, A 
reaction; lane 15, G reaction. Respective isotherms are shown below. 
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Table 3.5 Binding affinities (M
-1
) for polyamides 6R, 7R, 6S, and 7S. Equilibrium association 
constants are reported as mean values from three DNase I footprinting titration experiments. Standard 
deviations are shown in parentheses. 
 
 
 
Table 3.6 Relative binding affinities for polyamides 6R, 7R, 6S, and 7S. Relative binding affinities are 
reported as ratios of binding affinities (Ka) as determined by DNase I footprinting titration experiments 
for polyamides targeting 5’-WGGWW-3’.  
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3.3 Conclusions 
By utilizing six-ring hairpin polyamides, we were able to combine DNase I footprinting 
titration and duplex stabilization analyses in order to fully characterize the binding preferences of 
various hairpin turn subunits. Although the hairpin turns investigated herein show modest DNA 
binding specificities, we anticipate that further study will yield moieties enabling discrimination 
amongst all four Watson-Crick base pairs and add an additional recognition element for DNA 
recognition.  
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3.4 Materials and Methods 
Materials 
(S)-(-)-4-amino-2-hydroxybutyric acid, phthalic anhydride, solid sodium hydrogensulfonate 
(NaHSO4), 2M HCl in diethyl ether (Et2O), pyridine, diethylaminosulfur trifluoride (DAST), di-tert-
butyldicarbonate (Boc2O), triphenyl phosphine (PPh3), 4-nitrobenzoic acid, diisopropyl 
azodicarboxylate (DIAD), triethylamine, methyl iodide (CH3I ), 1 M aqueous HCl, anhydrous N,N-
dimethylformamide (DMF) and tryptamine were purchased from Sigma-Aldrich. 1M aqueous NaOH, 
concentrated HCl, solid sodium sulfate (Na2SO4), and solid sodium bicarbonate (NaHCO3) were 
purchased from EMD Chemicals. PyBOP and Boc-4-Abu-OH were purchased from NovaBioChem. 
Solid citric acid hexahydrate was purchased from Mallinckrodt Chemicals. (R)-2,4-Fmoc-Dbu(Boc)-
OH was purchased from Bachem. (R)-3,4-Cbz-Dbu(Boc)-OH and (S)-3,4-Cbz-Dbu(Boc)-OH were 
purchased from Senn Chemicals AG.  
 
Methods 
Enantiopurities of precursors were probed via analytical chiral HPLC assays of their tryptamide 
derivatives (Fig. 3.11 and 3.12). All DNA oligomers were purchased from Integrated DNA 
Technologies. Polyamides were purified via preparative HPLC on an Agilent Technologies 1200 
Series system using a Phenomenex Gemini column. Matrix-assisted, LASER desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) was performed on an Applied Biosystems 
Voyager DR Pro spectrometer. NMR spectroscopy data was obtained on a Variant instrument 
operating at 500 MHz. HRMS were acquired using an Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure chemical ionization 
(APCI) or mixed (MM) ionization mode. Optical rotation measurements were measured on a Jasco P-
1010 polarimeter at 589 nm in spectrophotometric grade solvents. 
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I. Polyamide Synthesis 
 Polyamides were synthesized with Boc-β-Ala-PAM resin (Peptides International) according to 
published synthesis protocols.
22, 29
 
 
Polyamide 1: MALDI-TOF [M+H]
+ 
calcd for C46H60N17O8
+
 = 979.1, observed = 978.8.  
Polyamide 2R: MALDI-TOF [M+H]
+ 
calcd for C46H62N18O8
+
 = 994.1, observed = 993.9.  
Polyamide 3R: MALDI-TOF [M+H]
+ 
calcd for C48H63N18O9
+
 = 1036.1, observed = 1036.0.  
Polyamide 4R: MALDI-TOF [M+H]
+ 
calcd for C46H62N18O8
+
 = 994.1, observed = 994.0. 
Polyamide 5R: MALDI-TOF [M+H]
+ 
calcd for C48H63N18O9
+
 = 1036.1, observed = 1035.9. 
Polyamide 4S: MALDI-TOF [M+H]
+ 
calcd for C46H62N18O8
+
 = 994.1, observed = 993.9. 
Polyamide 6R: MALDI-TOF [M+H]
+ 
calcd for C46H60N17O9
+
 = 995.1, observed = 995.0.  
Polyamide 7R: MALDI-TOF [M+H]
+ 
calcd for C46H59FN17O8
+
 = 996.5, observed = 996.7.  
Polyamide 6S: MALDI-TOF [M+H]
+ 
calcd for C46H60N17O9
+
 = 995.1, observed = 995.1. 
Polyamide 7S: MALDI-TOF [M+H]
+ 
calcd for C46H59FN17O8
+
 = 996.5, observed = 996.6. 
 
 
 
II. Synthesis of Fluoro and Hydroxyl Turn Precursors 
 
(S)-methyl 4-(1,3-dioxoisoindolin-2-yl)-2-hydroxy-butanoate (15). (S)-(-)-4-amino-2-hyroxybutyric 
acid (4.00 g, 33.6 mmol) 14 was combined with phthalic anhydride (4.97 g, 33.6 mmol). The solids 
were ground, mixed, and heated to 140
o
C, at which point the phthalic anhydride melted and dissolved 
14. After 30 min, the reaction mixture was cooled to room temperature and re-dissolved in EtOAc (300 
mL). The solution was extracted with 1 M NaHSO4 (100 mL, pH 3), washed with water (3 x 100 mL), 
and brine (100 mL). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. To 
the crude mixture (8.3 g) dissolved in anhydrous methanol (250 mL) was slowly added 2 M HCl in 
Et2O (250 mL). The reaction was stirred at room temperature; TLC indicated completion after 3 h. The 
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mixture was concentrated on rotovap and purified on a short silica gel column (9:1 DCM:EtOAc). The 
desired fractions were combined, concentrated and dried to give product 15 as a fine white powder 
(6.68 g, 76% yield). 
1
H NMR [499.8 MHz, DMSO-d6]:  7.83 (m, 4 H), 5.57 (d, J = 5.5 Hz, 1 H), 4.11 
(m, 1 H), 3.68 (t, J = 7.25 Hz, 2 H), 3.59 (s, 3 H), 2.01 (m, 1 H), 1.84 (m, 1 H); 
13
C NMR [125.7 MHz, 
DMSO-d6]:  173.9, 167.8, 134.3, 131.7, 122.9, 68.0, 51.5, 34,3, 32.2; HRMS (MM: ESI–APCI) calcd 
for C13H13NO5 [M+Na]
+
 286.0686, found 286.0684; []22D +10.40 (c = 0.5, CHCl3). 
 
(R)-methyl 4-(1,3-dioxoisoindolin-2-yl)-2-fluorobutanoate (16). To hydoxyl ester 15 (5.00 g, 19.0 
mmol) in DCM (50 mL) was added pyridine (1.923 mL, 23.7 mmol) at 0
o
C. The solution was purged 
with argon and DAST (3.11 mL, 23.7 mmol) was added dropwise under argon pressure. The reaction 
was stirred at room temperature for 18 h and poured slowly into a cold saturated NaHCO3 solution. 
The organic layer was extracted, washed with water (50 mL), 0.1 M HCl (50 mL), water (50 mL) and 
brine (50 mL), and dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified via 
silica gel column chromatography (DCM to 9:1 DCM:EtOAc). The desired fractions were combined, 
concentrated and dried to yield compound 16 as a pale yellow solid (2.21 g, 44% yield). 
1
H NMR 
[499.8 MHz, DMSO-d6]:  7.85 (m, 4 H), 5.24 (ddd, JH-H = 3.5 Hz, JH-H = 8.5 Hz, JH-F = 48 Hz, 2 H), 
3.72 (m, 2 H), 3.65 (s, 3 H), 2.09-2.29 (brm, 2 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  169.3 (2JC-F = 
23.5 Hz), 167.7, 134.3, 131.7, 123.0, 86.7 (
1
JC-F = 181.0 Hz), 52.2, 33.1 (
3
JC-F = 3.3 Hz), 30.3 (
2
JC-F = 
20.7 Hz); HRMS (MM: ESI–APCI) calcd for C13H12FNO4 [M+H]
+
 266.0823, found 266.0830; []22D -
2.64 (c = 0.5, CHCl3). 
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(R)-4-amino-2-fluorobutanoic acid (17). Ester 16 (300 mg, 1.13 mmol) was suspended in 6M HCl 
(3.0 mL) and refluxed for 16 h under argon pressure. The mixture was cooled to room temperature, the 
phthalic acid precipitate was removed by filtration. The filtrate was concentrated in vacuo, and the 
product was purified by recrystallization in iPrOH and Et2O to afford 17 as white crystals (124 mg, 
91% yield). 
1
H NMR [499.8 MHz, D2O]: 5.08 (ddd, JH-H = 4.0 Hz, JH-H = 8.0 Hz, JH-F = 49.0 Hz, 2 
H), 3.10 (m, 2 H), 2.09-2.32 (brm, 2 H); 
13
C NMR [125.7 MHz, D2O]:  173.4 (
2
JC-F = 23.0 Hz), 87.6 
(
1
JC-F = 180.0 Hz), 36.0 (
3
JC-F = 3.8 Hz), 29.6 (
2
JC-F = 20.7 Hz); HRMS (MM: ESI–APCI) calc’d for 
C4H8FNO4 [M+H]
+
 122.0612, found 122.061; []22D +10.64 (c = 0.5, H2O). 
 
(R)-4-(tert-butoxycarbonylamino)-2-fluorobutanoic acid (18). To a solution of amino acid 17 (40 mg, 
0.33 mmol) in THF (1 mL) and water (1 mL), solid NaHCO3 (83 mg, 0.99 mmol) and Boc2O (87 mg, 
0.40 mmol) was added at 0 
o
C. After 30 min, the solution was slowly warmed to room temperature and 
stirred for 16 h, followed by extraction with Et2O (2 x 1.5 mL) to remove generated tert-butanol and 
unreacted Boc2O. The aqueous layer was carefully acidified to pH 2.5 with half-saturated citric acid at 
0
o
C, and extracted with DCM (3x1.5mL). The combined organic phase was dried (Na2SO4), filtered, 
concentrated and dried to give product 18 as a colorless oil (52 mg, 71% yield).
 1
H NMR [499.8 MHz, 
DMSO-d6]:  13.4 (brs, 1 H), 6.91 (t, J = 5.5 Hz, 1 H), 4.95 (ddd, JH-H = 3.5 Hz, JH-H = 8.5 Hz, JH-F = 
49.0 Hz, 2 H), 3.04 (m, 2 H), 1.75-2.01 (brm, 2 H), 1.37 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  
170.9 (
2
JC-F = 23.0 Hz), 155.6, 86.6 (
1
JC-F = 180.5 Hz), 77.7, 35.7, 32.4 (
2
JC-F = 20.2 Hz), 28.2; HRMS 
(MM: ESI–APCI) calc’d for C9H16FNO4 [M-H]
-
 220.0991, found 220.1018; []22D +5.32 (c = 0.5, 
MeOH). 
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(R)-methyl 4-(1,3-dioxoisoindolin-2-yl)-2-hydroxy-butanoate (19). To a solution of 15 (5.00 g, 19.0 
mmol) in THF (125 mL) was added PPh3 (5.485 g, 20.9 mmol) followed by 4-nitrobenzoic acid (9.53 
g, 57.0 mmol). DIAD (4.06 mL, 20.9 mmol) was added dropwise to the solution at 0 
o
C, and the 
reaction was stirred at room temperature. TLC showed reaction completion after 4 h, and the solution 
was concentrated in vacuo. The product was isolated via silica gel column chromatography (100% 
DCM), and the combined fractions were concentrated and dried in vacuo to afford the Mitsunobu 
intermediate (R)-4-(1,3-dioxoisoindolin-2-yl)-1-methoxy-1-oxobutan-2-yl 4-nitrobenzoate as a pale 
yellow powder (7.3 g, 93% yield). 
1
H NMR [499.8 MHz, DMSO-d6]:  8.30 (dd, J = 2.5 Hz, J = 9 
Hz, 2 H), 8.17 (dd, J = 2.5 Hz, J = 9 Hz, 2 H), 7.78 (m, 4 H), 5.33 (dd, J = 5 Hz, J = 7.5 Hz, 1 H), 3.84 
(m, 2 H), 3.65 (s, 3 H), 2.33 (m, 2 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  169.4, 167.9, 163.6, 
150.4, 134.3, 134.0, 131.6, 130.7, 123.9, 123.0, 71.2, 52.5, 33.9, 30.0; HRMS (MM: ESI–APCI) calc’d 
for C20H16N2O8 [M+H]
+
 413.0979, found 413.0975; []22D +28.6 (c = 0.5, CHCl3). 
 To obtain the desired product 19, triethylamine (9.93 mL, 77.5 mmol) was added to the 
intermediate (6.4 g, 15.5 mmol) in anhydrous methanol (480 mL). The reaction was monitored by TLC 
and was complete after 4 h. The solution was then concentrated and purified via column 
chromatography (DCM to 9:1 DCM:EtOAc). The desired fractions were combined, concentrated and 
dried to afford compound 19 as a fine white powder (3.86 g, 95% yield). 
1
H NMR [499.8 MHz, 
DMSO-d6]:  7.84 (m, 4 H), 5.57 (d, J = 5.5 Hz, 1 H), 4.12 (m, 1 H), 3.68 (t, J = 7.5 Hz, 2 H), 3.59 (s, 
3 H), 2.02 (m, 1 H), 1.84 (m, 1 H); 
13
C NMR [125.7 MHz, DMSO-d6]: 173.9, 167.8, 134.3, 131.7, 
122.9, 67.9, 51.5, 34.3, 32.1; HRMS (MM: ESI–APCI) calc’d for C13H13NO5 [M+Na]
+
 286.0686, 
found 286.0688; []22D -10.28 (c = 0.5, CHCl3). 
 
(S)-methyl 4-(1,3-dioxoisoindolin-2-yl)-2-fluorobutanoate (20). Synthesis was performed using R-
enantiomer 19 (3.85 g, 14.6 mmol) in conjunction with the method for the synthesis of fluoroester 16. 
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The product 20 was synthesized and isolated as a pale yellow solid (1.60 g, 41% yield). 
1
H NMR 
[499.8 MHz, DMSO-d6]: 7.85 (m, 4 H), 5.24 (ddd, JH-H = 3.5 Hz, JH-H = 8.5 Hz, JH-F = 48.0 Hz, 2 H), 
3.72 (m, 2 H), 3.65 (s, 3 H), 2.09-2.29 (brm, 2 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  169.3 (2JC-F = 
23.5 Hz), 167.7, 134.3, 131.7, 123.0, 86.7 (
1
JC-F = 181.3 Hz), 52.2, 33.1 (
3
JC-F = 3.8 Hz), 30.3 (
2
JC-F = 
20.2 Hz); HRMS (MM: ESI–APCI) calc’d for C13H12FNO4 [M+H]
+
 266.0823, found 266.0828; []22D 
+2.4 (c = 0.5, CHCl3). 
 
(S)-4-amino-2-fluorobutanoic acid (21). This compound was synthesized by following the method 
used for the synthesis of amino acid 17, but using the S-enantiomer 20 (1.60 g, 6.03 mmol) as starting 
material. The product was synthesized and isolated as fluffy white crystals (725 mg, 99% yield).
 1
H 
NMR [499.8 MHz, D2O]:  5.08 (ddd, JH-H = 4.0 Hz, JH-H = 8.0 Hz, JH-F = 49.0 Hz, 2 H), 3.09 (m, 2 H), 
2.08-2.32 (brm, 2 H); 
13
C NMR [125.7 MHz, D2O]:  173.4 (
2
JC-F = 23.0 Hz), 87.7 (
1
JC-F = 180.0 Hz), 
36.0 (
3
JC-F = 3.3 Hz), 29.6 (
2
JC-F = 20.7 Hz); HRMS (MM: ESI–APCI) calc’d for C4H8FNO4 [M+H]
+
 
122.0612, found 122.0613; []22D -11.2 (c = 0.5, H2O). 
 
 (S)-4-(tert-butoxycarbonylamino)-2-fluorobutanoic acid (22). This compound was synthesized by 
following the method used for the synthesis of amino acid 18, but using the S-enantiomer 21 (40 mg, 
0.33 mmol) as starting material. The product 22 was synthesized and isolated as a colorless oil (51 mg, 
70% yield). 
1
H NMR [499.8 MHz, DMSO-d6]:  13.3 (brs, 1 H), 6.91 (t, J = 5.5 Hz, 1 H), 4.95 (ddd, 
JH-H = 3.5 Hz, JH-H = 8.5 Hz, JH-F = 49.0 Hz, 2 H), 3.04 (m, 2 H), 1.75-2.01 (brm, 2 H), 1.37 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  170.8 (2JC-F = 23.5 Hz), 155.4, 86.4 (
1
JC-F = 180.5 Hz), 77.6, 
35.6, 32.3 (
2
JC-F = 19.9 Hz), 28.1; HRMS (MM: ESI–APCI) calc’d for C9H16FNO4 [M-H]
-
 220.0991, 
found 220.1017; []22D -5.04 (c = 0.5, MeOH). 
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(S)-4-(tert-butoxycarbonylamino)-2-hydroxybutanoic acid (23). To a solution of (S)-(-)-4-amino-2-
hydroxybutyric acid 14 (2.00 g, 16.8 mmol) dissolved in water (50 mL) and 1,4-dioxane (50 mL), 
NaHCO3 (1.55 g, 18.5 mmol) and added Boc2O (4.04 g, 18.5 mmol) was added at 0 
o
C. After 15 min, 
the turbid solution was slowly warmed to room temperature and stirred for 16 h. The solution was 
extracted with Et2O (2 x 50mL) to rid of the generated tert-butanol and unreacted di-tert-
butyldicarbonate. The aqueous layer was carefully acidified to pH 2.5 with 1 M HCl (~20 mL) at 0 
o
C, 
and extracted with DCM (3 x 50mL). The combined organic phase was dried (Na2SO4), filtered, 
concentrated and dried to give product 23 as a colorless oil (3.03 g, 82% yield). 
1
H NMR [499.8 MHz, 
DMSO-d6]:  6.75 (t, J = 5.0 Hz, 1 H), 3.93 (dd, J = 4.0 Hz, J = 8.5 Hz, 1 H), 3.00 (m, 2 H), 1.77 (m, 
1 H), 1.57 (m, 1 H), 1.36 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  175.6, 155.5, 77.5, 67.7, 36.7, 
34.1, 28.2; HRMS (MM: ESI–APCI) calc’d for C9H17NO5 [M+Na]
+
 242.0999, found 242.0997; []22D 
-3.96 (c = 0.5, MeOH). 
 
(S)-methyl 4-(tert-butoxycarbonylamino)-2-hydroxybutanoate (24). To a solution of Boc-protected 
amino acid 23 (2.00 g, 9.1 mmol) dissolved in DMF (20 mL) was added K2CO3 (1.32 g, 9.54 mmol) at 
0 
o
C. After 15 min, CH3I (4.13 g, 29.12 mmol) was added slowly and the solution was stirred for 44 h 
at room temperature. The solution was then partitioned between H2O (100 mL) and ethyl acetate (4 x 
50 mL). The organic fractions were combined, dried (Na2SO4), filtered, concentrated and dried to give 
product 24 as a pale yellow oil (1.20 g, 57% yield).
 1
H NMR [499.8 MHz, DMSO-d6]:  6.76 (t, J = 
5.0 Hz, 1 H), 5.39 (d, J = 6.0 Hz, 1 H), 4.04 (m, 1 H), 3.62 (s, 3 H), 2.99 (m, 2 H), 1.75 (m, 1 H), 1.59 
(m, 1 H), 1.36 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]: 174.4, 155.5, 77.5, 67.8, 51.4, 36.4, 34.1, 
28.2; HRMS (MM: ESI–APCI) calc’d for C10H19NO5 [M+Na]
+
 256.1155, found 256.1159; []22D 
+4.56 (c = 0.5, MeOH). 
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(R)-methyl 4-(tert-butoxycarbonylamino)-2-hydroxybutanoate (25). To a solution of ester 24 (650 
mg, 2.75 mmol) in THF (13 mL) was added PPh3 (795 g, 3.02 mmol) followed by 4-nitrobenzoic acid 
(1.38 g, 8.26 mmol). DIAD (589 L, 3.03 mmol) was added dropwise to the solution at 0 oC, and the 
reaction was stirred at room temperature. TLC showed a completed reaction after 8 h, and the solution 
was concentrated in vacuo. The product was isolated via silica gel column chromatography (95:5 
DCM:EtOAc to 9:1 DCM:EtOAc), and the combined fractions were concentrated and dried in vacuo 
to afford the Mitsunobu intermediate (R)-4-(tert-butoxycarbonylamino)-1-methoxy-1-oxobutan-2-yl 4-
nitrobenzoate as a colorless oil (890 mg, 84% yield). 
1
H NMR [499.8 MHz, DMSO-d6]:  8.38 (dd, J 
= 2.0 Hz, J = 9.0 Hz, 2 H), 8.24 (dd, J = 2.0 Hz, J = 9.0 Hz, 2 H), 6.99 (t, 5.5 Hz, 1 H), 5.20 (m, 1 H), 
3.70 (s, 3 H), 3.16 (m, 2 H), 2.05 (m, 2 H), 1.34 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  169.9, 
163.8, 155.6, 150.5, 134.3, 130.8, 124.0, 77.7, 70.9, 52.4, 35.8, 30.8, 28.1; HRMS (MM: ESI–APCI) 
calc’d for C17H2N2O8 [M-Boc+2H]
+
 283.0925, found 283.0934; []22D +16.64 (c = 0.5, MeOH). 
 To obtain the desired product 25, triethylamine (750 L, 5.38 mmol) was added to the 
intermediate (410 mg, 1.07 mmol) in anhydrous methanol (30 mL). The reaction was monitored by 
TLC and was complete after 1.5 h. The solution was then concentrated and run through a silica plug. 
DCM was run till the eluent was no longer UV active, at which point EtOAc was used to flush out the 
product. The EtOAc fractions were combined, concentrated and dried to afford compound 25 as a pale 
yellow oil (250 mg, 99% yield). 
1
H NMR [499.8 MHz, DMSO-d6]: 6.76 (t, J = 5.0 Hz, 1 H), 5.39 (d, 
J = 6.0 Hz, 1 H), 4.04 (m, 1 H), 3.62 (s, 3 H), 2.99 (m, 2 H), 1.76 (m, 1 H), 1.60 (m, 1 H), 1.36 (s, 9 
H); 
13
C NMR [125.7 MHz, DMSO-d6]: 174.4, 155.5, 77.5, 67.8, 51.4, 36.5, 34.1, 28.2; HRMS 
(MM: ESI–APCI) calc’d for C10H19NO5 [M+Na]
+
 256.1155, found 256.1158; []22D -4.28 (c = 0.5, 
MeOH). 
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(R)-4-(tert-butoxycarbonylamino)-2-hydroxybutanoic acid (26). To a solution of Boc-protected 
amino acid 25 in MeOH (2.5 mL) was added dropwise 1M NaOH (2.5 mL) at 0
o
C. The reaction 
mixture was warmed to room temperature and TLC showed a completed reaction after 30 min. The 
solution was cooled to 0 
o
C and re-acidified to pH2 by dropwise addition of 1 M HCl (2.5 mL), and 
extracted with EtOAc (3 x 2.5 mL). The organic fractions were then combined, dried (Na2SO4), 
filtered, concentrated and dried to give product 26 as a colorless oil (108 mg, 93% yield). 
1
H NMR 
[499.8 MHz, DMSO-d6]: 6.75 (t, J = 5.0 Hz, 1 H), 3.92 (dd, J = 4.0 Hz, J = 8.5 Hz, 1 H), 3.00 (m, 2 
H), 1.77 (m, 1 H), 1.56 (m, 1 H), 1.36 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  175.6, 155.5, 
77.4, 67.8, 36.7, 34.1, 28.2; HRMS (MM: ESI–APCI) calc’d for C9H17NO5 [M+Na]
+
 242.0999, found 
242.0998; []22D +4.12 (c = 0.5, MeOH). 
 
(R)-tert-butyl 4-(2-(1H-indol-3-yl)ethylamino)-3-fluoro-4-oxobutylcarbamate (27).  To a solution of 
Boc-protected amino acid 18 (25 mg, 0.11 mmol) in anhydrous DMF (1.0 mL) was added tryptamine 
(91 mg, 0.55 mmol), followed by PyBOP (65 mg, 0.12 mmol). The reaction was stirred at room 
temperature for 1.5 h, and subsequently partitioned between H2O (1 mL) and EtOAc (3 x 1 mL). The 
organic layers were then combined, washed with 10% citric acid (3 x 1 mL), saturated NaHCO3 (3 x 1 
mL), brine, dried (Na2SO4), filtered, and concentrated. The product was purified on a silica gel column 
(9:1 Et2O:EtOAc), and the desired fractions were combined, concentrated and dried to afford the 
desired product 27 as a pale yellow oil (28 mg, 68%). 
1
H NMR [499.8 MHz, DMSO-d6]: 10.80 (s, 1 
H), 8.26 (t, J = 5.5 Hz, 1 H), 7.53 (d, J = 8.0 Hz, 1 H), 7.32 (app dt, J = 1.0 Hz, J = 8.0 Hz, 1 H), 7.14 
(d, J = 2.5 Hz, 1 H), 7.05 (ddd, J = 1.0 Hz, J = 7.0 Hz, J = 7.0 Hz, 1 H), 6.97 (ddd, J = 1.0 Hz, J = 7.0 
Hz, J = 7.0 Hz, 1 H), 6.87 (t, J = 5.5 Hz, 1 H), 4.88 (ddd, J = 3.5 Hz, J = 8.5 Hz, J = 49.5 Hz, 1 H), 
3.38 (m, 2 H), 3.03 (m, 2 H), 2.84 (t, 7.5 Hz, 2 H), 1.76-1.95 (m, 2 H), 1.37 (s, 9 H); 
13
C NMR [125.7 
MHz, DMSO-d6]:  168.7 (2JC-F = 19.9 Hz), 155.3, 136.2, 127.2, 122.6, 120.9, 118.3, 118.2. 111.6, 
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111.3, 89.3 (
1
JC-F = 181.9 Hz), 77.6, 35.7, 32.7 (
2
JC-F = 20.7 Hz), 28.2, 25.0; HRMS (MM: ESI–APCI) 
calc’d for C19H26FN3O3 [M+Na]
+
 386.1850, found 386.1855; []22D +17.1 (c = 0.5, MeOH). 
 
(S)-tert-butyl 4-(2-(1H-indol-3-yl)ethylamino)-3-fluoro-4-oxobutylcarbamate (28). This compound 
was synthesized by following the method used for the synthesis of amide 27, but instead using the S-
enantiomer 23 (23 mg, 0.10 mmol) as starting material. The product 28 was synthesized and isolated as 
a pale yellow oil (25 mg, 66% yield).
 1
H NMR [499.8 MHz, DMSO-d6]: 10.80 (s, 1 H), 8.26 (t, J = 
5.5 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 1 H), 7.32 (app dt, J = 1.0 Hz, J = 8.0 Hz, 1 H), 7.14 (d, J = 2.0 Hz, 1 
H), 7.05 (ddd, J = 1.0 Hz, J = 7.0 Hz, J = 7.0 Hz, 1 H), 6.97 (ddd, J = 1.0 Hz, J = 7.0 Hz, J = 7.0 Hz, 1 
H), 6.87 (t, J = 5.5 Hz, 1 H), 4.88 (ddd, J = 3.5 Hz, J = 8.5 Hz, J = 49.5 Hz, 1 H), 3.38 (m, 2 H), 3.03 
(m, 2 H), 2.84 (t, 7.5 Hz, 2 H), 1.76-1.95 (m, 2 H), 1.37 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  
168.8 (
2
JC-F = 19.7 Hz), 155.6, 136.2, 127.2, 122.6, 120.9, 118.3, 118.2. 111.6, 111.4, 89.3 (
1
JC-F = 
182.8 Hz), 77.7, 35.7, 32.7 (
2
JC-F = 19.9 Hz), 28.2, 25.0; HRMS (MM: ESI–APCI) calc’d for 
C19H26FN3O3 [M+Na]
+
 386.1850, found 386.1855; []22D -16.6 (c = 0.5, MeOH). 
 
(S)-tert-butyl 4-(2-(1H-indol-3-yl)ethylamino)-3-hydroxy-4-oxobutylcarbamate (29). To a solution of 
Boc-protected amino acid 23 (24 mg, 0.11 mmol) in anhydrous DMF (1.0 mL) was added tryptamine 
(89 mg, 0.55 mmol), followed by PyBOP (64 mg, 0.12 mmol). The reaction was stirred at room 
temperature for 1.5 h, and subsequently partitioned between H2O (1 mL) and EtOAc (3 x 1 mL). The 
organic layers were then combined, washed with 10% citric acid (3 x 1 mL), saturated NaHCO3 (3 x 1 
mL), brine, dried (Na2SO4), filtered, and concentrated. The product was purified on a silica gel column 
(9:1 Et2O:EtOAc), and the desired fractions were combined, concentrated and dried to afford the 
desired product 29 as a pale yellow oil (25 mg, 62%). 
1
H NMR [499.8 MHz, DMSO-d6]: 10.8 (s, 1 
H), 7.80 (t, J = 6.0 Hz, 1 H), 7.56 (d, J = 8.0 Hz, 1 H), 7.32 (app dt, J = 1Hz, J = 8.0Hz, 1 H), 7.14 (d, 
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J = 2.5 Hz, 1 H), 7.05 (ddd, J = 1.0 Hz, J = 7.0 Hz, J = 7.0 Hz, 1 H), 6.97 (ddd, J = 1.0 Hz, J = 7.0 Hz, 
J = 7.0 Hz, 1 H), 6.71 (t, J =  5.5 Hz, 1 H), 3.84 (m, 1 H), 3.36 (m, 2 H), 3.00 (m, 2 H), 2.82 (t, J = 8.0 
Hz, 2 H), 1.78 (m, 1 H), 1.52 (m, 1 H), 1.37 (s, 9 H); 
13
C NMR [125.7 MHz, DMSO-d6]:  173.5, 
155.6, 136.3, 127.2, 122.6, 120.9, 118.3, 118.2, 111.7, 111.3, 77.5, 69.2, 36.8, 34.7, 28.3, 25.3; HRMS 
(MM: ESI–APCI) calc’d for C19H27N3O4 [M+Na]
+
 384.1894, found 384.1894; []22D -14.4 (c = 0.5, 
MeOH). 
 
(R)-tert-butyl 4-(2-(1H-indol-3-yl)ethylamino)-3-hydroxy-4-oxobutylcarbamate (30). This compound 
was synthesized by following the method used for the synthesis of amide 29, but instead using the R-
enantiomer 25 (10 mg, 0.0 5mmol) as starting material. The product 30 was synthesized and isolated as 
a pale yellow oil (11 mg, 66% yield).
 1
H NMR [499.8 MHz, DMSO-d6]: 10.8 (s, 1 H), 7.80 (t, J = 
6.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1 H), 7.32 (app dt, J = 1Hz, J = 8.0Hz, 1 H), 7.14 (d, J = 2.5 Hz, 1 H), 
7.05 (ddd, J = 1.0 Hz, J = 7.0 Hz, J = 7.0 Hz, 1 H), 6.97 (ddd, J = 1.0 Hz, J = 7.0 Hz, J = 7.0 Hz, 1 H), 
6.71 (t, J =  5.5 Hz, 1 H), 3.84 (m, 1 H), 3.36 (m, 2 H), 3.00 (m, 2 H), 2.82 (t, J = 8.0 Hz, 2 H), 1.78 
(m, 1 H), 1.52 (m, 1 H), 1.37 (s, 9 H); [125.7 MHz, DMSO-d6]:  173.5, 155.6, 136.2, 127.2, 122.6, 
120.9, 118.3, 118.2, 111.7, 111.3, 77.5, 69.2, 36.8, 34.7, 28.3, 25.3; HRMS (MM: ESI–APCI) calc'd 
for C19H27N3O4 [M+Na]
+
 384.1894, found 384.1897; []22D +15.0 (c = 0.5, MeOH) 
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III. Analytical Chiral HPLC Assays for 28–31. 
The enantiopurity of compounds 18, 22, 23 and 26 were determined by chiral HPLC assays 
performed on the UV active tryptamide derivatives 27–30 (Fig. 3.11 and 3.12). The assays were taken 
on an Agilent 1100 Series HPLC utilizing a Chiralpak AD column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. 
 
IV. DNA Thermal Denaturation Assays 
 
Melting temperature analysis was performed as previously described
22
 on a Varian Cary 100 
spectrophotometer equipped with a thermo-controlled cell holder, using 10 mM sodium cacodylate 
buffer. 
 
V. DNase I Footprinting Assays 
Plasmids were constructed as previously described
18
 by annealing the following oligonucleotide pair: 
5’-AGCTGCTGACTGACTATGGTTCTGACTGACTATGGTACTGACTGACTATGGTCCTGAC-
TGACTATGGTGCTGACTGACTGCCGC-3’ and 5’-GATCGCGGCAGTCAGTCAGCACCATAG-
TCAGTCAGGACCATAGTCAGTCAG-TACCATAGTCAGTCAGAACCATAGTCAGTCAGC-3’. 
5’ labeling of primers with 32P and subsequent DNase I footprinting titrations were performed as 
previously described.
18, 25
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Figure 3.8 Analytical chiral HPLC assays for fluoro turn tryptamide derivatives 27 and 28. (Top) 
Racemic mixture of 27 and 28; (middle) R-enantiomer 27; (bottom) S-enantiomer 28. 
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Figure 3.9 Analytical chiral HPLC assays for hydroxyl turn tryptamide derivatives 29 and 30. (Top) 
Racemic mixture of 29 and 30; (middle) S-enantiomer 29; (bottom) R-enantiomer 30. 
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3.7 Experimental Data 
 
 
 
Figure 3.10 Chemical and ball-and-stick structures of polyamides targeted to 5’-WGWWW-3’ (8–10) 
and 5’-WGGCW-3’ (11–13) sequences. Ball and stick symbols are defined as follows: pyrrole is 
denoted by an open circle, imidazole is denoted by a filled circle, and β-alanine is denoted by a 
diamond shape. 
 
 
 
 
Table 3.7 Melting temperatures of DNA/polyamide complexes 8–13. All values are derived from at 
least three melting temperature experiments, with standard deviations indicated in parentheses. Tm 
values are given as Tm (DNA/polyamide) - Tm (DNA).   
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Figure 3.11 Quantitative DNase I footprinting titration experiments on (a) plasmid pCDMF4 for 
polyamides (b) 8–10. Lanes 1–11, 100 nM, 30 nM, 10 nM, 3 nM, 1 nM, 300 pM, 100 pM, 30 pM, 10 
pM, 3 pM, and 1 pM, respectively; lane 12, DNase I standard; lane 13, intact DNA; lane 14, A 
reaction; lane 15, G reaction. Respective binding isotherms are shown below. (c) Table of equilibrium 
assocations constants, reported as mean values from three DNase I footprinting titration experiments. 
Standard deviations are shown in parentheses. 
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Table 3.8 Relative binding affinities for polyamides 8–10. (a) Relative binding affinities are reported 
as ratios of binding affinities (Ka) as determined by DNase I footpinting titration experiments for 
polyamides targetting 5’-WGWWW-3’.  Sites containing G•C and C•G at the hairpin position have 
relative affinities < 0.01 (not  shown). 
 
 
 
 
 
 
Table 3.9 Melting temperatures of DNA/polyamide complexes for 6R, 7R, 6S, and 7S. All values are 
derived from at least three melting temperature experiments, with standard deviations indicated in 
parentheses. ΔTm values are given as Tm (DNA/polyamide) − Tm (DNA). 
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the Biological Studies of Hairpin Polyamides 
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Abstract 
 Py-Im polyamides targeted to the sequence 5’-WGWWCW-3’, found in the consensus 
androgen response element (ARE), have been used to modulate AR-mediated gene transcription 
in LNCaP prostate cancer cell lines. To study these biological effects in an animal model, hairpin 
polyamides 1 and 2 have been administered to mice for pharmacokinetic characterization. The 
antitumor activity of 1 was further analyzed in a prostate tumor xenograft mode, and the mice 
treated with 1 had smaller tumors and lower serum prostate-specific antigen (PSA) compared to 
untreated controls. In an effort to expand the scope of biological targets, polyamide 3 targeted to 
the estrogen response element (ERE) has also been synthesized and displayed favorable gene 
regulatory effects in T47D-KBLUC breast cancer cells and xenograft models. 
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4.1. Introduction 
 The androgen receptor (AR) is a member of the nuclear hormone receptor family of 
transcription factors.
1
 Upon ligand binding, AR is released from the cytoplasm and translocated 
to the nucleus, where AR dimers can bind to the androgen response elements (ARE) of target 
genes and activate transcription.
2
 AR-mediated gene expression is essential to normal prostate 
development and contributes to the progression of prostate cancer.
3
 While anti-androgen 
therapies are initially successful in slowing prostate cancer growth, nearly all patients eventually 
develop hormone refractory disease.
4-6
 Rather than targeting the AR ligand-binding domain, 
direct perturbation of the AR–ARE interactions may disrupt AR-induced transcriptional activity 
even in hormone-refractory conditions. Py-Im polyamide 1, designed to bind the 5’-
WGWWCW-3’ sequence found in the consensus ARE, was previously shown to downregulate 
the expression of AR-driven genes in LNCaP prostate cancer cells.
7 
 To further investigate the antitumor activity of ARE-targeted polyamides in animal 
models, hairpin polyamides 1 and 2 have been administered to both normal and LNCaP-
engrafted mice. Compared to cell culture assays, animal studies often require significantly larger 
quantities of polyamide substrates. By combining solution-phase tetramer synthesis methods and 
microwave-assisted solid-phase techniques,
8,9
 1 and 2 have been regularly synthesized on a 50-
mg scale in an efficient and reliable manner. The pharmacokinetic profiles of 1 and 2 were then 
analyzed by intravenous (IV) tail vein injection into normal mice. While the biodistribution and 
toxicity profiles were significantly different, the plasma concentrations of both compounds were 
measured at levels higher than required for gene regulation in cell culture. Since it was less toxic 
to the animal host, 1 was administered subcutaneously (SC) to mice engrafted with LNCaP cells. 
Compared to vehicle controls, the mice treated with three injections of 1 had smaller tumors and 
decreased serum PSA levels. 
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 While this in vivo toxicity is consistent with the perturbation of AR-mediated 
transcription by 1, there has also been mounting evidence in support of two alternate 
mechanisms. Genome-wide mapping of RNA polymerase II (RNAP2) occupancy using ChIP-
seq showed preferential perturbation by 1 at transcription start sites (TSS). Along with an 
observed decrease in RNAP2 large subunit RPB1 levels following polyamide treatment, this 
suggests that the tumor reduction effects may result from inhibition of RNAP2 activity. The pro-
apoptotic activity of 1 in AR-negative DU145 cells supports an AR- independent mechanism. 
Cell cycle analysis revealed polyamide-induced S-phase accumulation caused by inhibition of 
replicative helicase and subsequent stalling of replication forks. Although it is unclear how each 
of these pathways contributes toward tumor toxicity, it has been shown that the antitumor 
activity of 1 is not a result of DNA damage. 
 
 
Figure 4.1 Chemical structure and binding preferences of the Py-Im polyamides 1 and 2. (A) 
Chemical structure showing the two different turn functionalities. (B) Ball-and-stick 
representation of the polyamides. Open circles represent N-methylpyrrole residues, filled circles 
represent N-methylimidazoles. The hexagon represents the isophthalic acid moiety. (C) Hairpins 
1 and 2 bind the same 5’-WGWWCW-3’ DNA sequence, where W = A or T. 
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 In a parallel effort to expand the scope of biological targets, polyamide 3 targeted to the 
5’-WGGWCW-3’ sequence found in the estrogen response element (ERE) was used to modulate 
estrogen receptor (ER)-mediated transcription in T47D-KBLUC breast cancer cells. Upon 
treatment with 3, the expression of E2-activated genes such as TFF1 and WT1 were 
downregulated, whereas E2-supressed expression of TGFB2 was de-repressed. Furthermore, 3 
was administered into mice engrafted with T47D-KBLUC, and the luciferase output in 
polyamide-treated mice were significantly lower compared to untreated controls. Unlike 
treatment with 1, however, the tumor sizes remained largely unaffected by 3, even under an 
extended 9-dose regimen.  
 
4.2 Results and Discussion 
I. Microwave-Assisted Synthesis of Hairpin Polyamides 
 As our biological research has progressed from cell culture to mice models, the reliable 
and efficient synthesis of hairpin polyamides has become crucial. With the recent development in 
microwave-assisted methods, the solid-phase synthesis of an 8-ring polyamide core can now be 
completed within days at dramatically improved yields of up to 56% recovery.
9
 In order to 
further improve and expedite the synthetic process to meet increasing demands for biological 
assays, the synthesis of polyamides 1–3 have been further streamlined by combining the use of 
tetramers 6 and 7 under microwave-assisted conditions (Fig. 4.2). In this retrosynthetic approach, 
the polyamide cores 15–17 were quickly assembled from intermediate 12 by sequential 
couplings of turn 9 or 10 and tetramer 6 or 7. Following amine cleavage of 15–17, the 
isophthalate conjugation, turn deprotection and acetylation steps have all been optimized in a 
peak-to-peak fashion (Fig. S4.1–S4.3). The DNA binding properties of 1–3 to the corresponding 
match sequences have been assessed by thermal denaturation assays (Fig. S4.4–S4.6). 
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Figure 4.2 Retrosynthetic strategy towards hairpin polyamides 1-3. 
 
While the chiral turn units 9 and 10 are both commercially available and 6 has been 
obtained on a gram scale,
8
 the synthesis of 7 has not been previously reported. Starting with the 
ImIm-OH dimer, coupling with HCl•NH2-PyPy-OMe under PyBOP-activated conditions 
afforded 8, which was then saponified under basic conditions to afford tetramer 7 in 83% yield. 
 
Scheme 4.1 Synthesis of tetramer intermediate 7 
 
1
Reagents and conditions: (i) PyBOP, DIEA, DMF; (ii) NaOH, MeOH. 
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The polyamide cores 15-17 were rapidly assembled on oxime resin via microwave-
assisted conditions. Following the initial loading of BocPyOH to give 11, three deprotection-
coupling cycles with the corresponding monomers using the published protocols yielded 
intermediate 12. The turn units 9 or 10 were then coupled under microwave irradiation to afford 
13 or 14. In particular, the protection group strategy on turn 9 and thereby 13 was reversed from 
the traditional Fmoc-D-Dab(Boc)-OH turn. This circumvented the need to deprotect the Fmoc 
turn and replace it with a Boc group following completion of the polyamide core, and was made 
possible only by using the tetramers 6 and 7. Deprotection of the terminal Fmoc group in 13 
using 20% piperidine, or the terminal Boc group in 14 using 80% trifluoroacetic acid (TFA), 
followed by microwave-assisted coupling of 6 or 7, yielded polyamide core 15–17. 
 
Scheme 4.2 Solid-phase assembly of polyamide cores 15–17 
 
 
1
All PyBOP-mediated coupling conditions were performed under microwave-assisted conditions (Ref. 9) 
2
Reagents and conditions: (i) BocPyOH, PyBOP, DIEA, DMF; (ii) 80% TFA, DCM; (iii) BocPyOH, PyBOP, DIEA, 
DMF; (iv) 80% TFA, DCM; (v) BocPyOH, PyBOP, DIEA, DMF; (vi) 80% TFA, DCM; (vii) BocImOH, PyBOP, 
DIEA, DMF; (viii) 80% TFA, DCM; (ix) 9 (for 1, 3 & 5) or 10 (for 2 & 4), PyBOP, DIEA, DMF; (x) 20% 
piperidine in DMF (for 1, 3 & 5) or 80% TFA in DCM (for 2 & 4); (xi) 6 (for 1, 2, 4 & 5) or 7 (for 3), PyBOP, 
DIEA, DMF. 
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 Starting from 15–17, polyamides 1–5 were then obtained in several optimized steps in 
24–37% yield overall. Cleavage of the resin-bound 15–17 with neat 3,3’-diamino-N-
methyldipropylamine under microwave irradiation afforded triamine intermediates 18-20, which 
were purified by HPLC and recovered in 36-52% yield. Previous concerns on the epimerization 
of the chiral turn amino group by these relatively harsh conditions were mitigated by reports 
from Puckett et al, which showed a retained stereochemistry of the Mosher amide derivatives 
using UPLC assays.
9
 Isophthalic acid conjugation onto the tail primary amine of 18–20, followed 
by turn deprotection under acidic conditions, afforded polyamides 1, 4 and 3. Finally, 5 and 2 
were obtained by acetylation of the amino turn in 1 and 4, respectively. 
 
Scheme 4.3 Synthesis of hairpin polyamides 1–5 
 
1
Reagents and conditions: (i) 3,3’-diamino-N-methyldipropylamine; (ii) Isophthalic acid, PyBOP, DIEA, DMF; (iii) 
TFA (for 1, 3 & 5) or 10% TFMSA in TFA (for 2 & 4); (iv) Ac2O, pyridine, DMF (for 2 & 5).  
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II. Pharmacokinetic Studies of Polyamides 1 and 2 
 
 Recently, polyamide 1 designed to bind a 5’-WGWWCW-‘3 sequence found in the 
consensus androgen response element (ARE), and thereby disrupt the androgen receptor (AR)- 
ARE interaction, was found to decrease the expression of AR-driven genes in LNCaP prostate 
cancer cells under dihydrotestosterone (DHT)- induced conditions.
7
 Polyamide derivative 2 has 
been developed and shown to exhibit the equivalent activity to 1 at ten-fold less concentration.
10
 
In order to extend our research on the antitumor activity of polyamides in vivo, we have 
characterized the pharmacokinetic (PK) and toxicology profiles of 1 and 2 in mice models. 
 Following polyamide administration by a single intravenous tail injection, the blood 
plasma concentrations of 1 and 2 were monitored at various time points over a 24-hour time 
period using LC/MS/MS methods (Fig. 4.3A). Interestingly, despite an higher initial dose of 7.5 
mg/kg for 1, relative to 5 mg/kg for 2, the area under the concentration curve (AUC) of 1 (67.5 
g/mL x hr) was twofold lower than 2 (144.8 g/mL x hr). Tissue analysis further revealed a 
significantly higher concentration of 2 in liver, kidney and lung samples (301.3, 424.7 and 523.5 
g/mL x hr, respectively), as compared to 1 (157.7, 299.2 and 130.6 g/mL x hr, respectively) 
(Fig. 4.3B). Additionally, weight curve experiments showed polyamide 2 to be more toxic than 1 
(Fig. 4.3C). Animals treated with 1 only showed significant weight loss at the highest single 
injection of 10 mg/kg and otherwise displayed no signs of physical duress, whereas the mice 
administered with 4.5 mg/kg and 2.3 mg/kg doses of 2 not only lost more than 15% of body mass 
but also exhibited additional signs of physical duress. While the exact mechanisms behind these 
differences remain unclear, this nonetheless highlights the significant effects of minor structural 
modifications in mice models, and forms a valuable foundation for our future studies in vivo. 
139 
 
 
Figure 4.3 Biodistribution and toxicity profile of 1 and 2 in mice. (A) Plasma concentration 
versus time curves for 1 (closed circles) and 2 (open circles). Error bars indicate standard 
deviation. (B) Tissue pharmacokinetic parameters of 1 and 2 after a single IV injection. (C) 
Animal toxicity experiments for polyamides 1 and 2. Animals were injected on day 0 and 
monitored for 7 days for weight loss and signs of duress. Error bars indicate standard deviation, n 
= 4 (*n = 3). 
 
 
III. Antitumor Activity of Polyamide 1 in Prostate Tumor Xenografts 
 After establishing the PK and toxicity profiles of 1 in mice, we set forth to explore its 
antitumor activity in a prostate tumor xenograft model. Male immunocompromised NOD scid 
gamma (NSG) mice were engrafted with LNCaP cells (2.5 million cells) and the tumors were 
allowed to grow to ~ 100 mm
3
 prior to treatment. Vehicle control or 20 nmol (~ 1.4 mg/kg) 
polyamide 1 was then administered by subcutaneous (SC) injection once every 3 days. Following 
a cycle of three injections, the mice treated with 1 had noticeably smaller tumors (mean = 112 
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mg) compared to vehicle controls (mean = 310 mg) (Fig. 4.4A). Furthermore, serum PSA levels 
were measured by ELISA and found to be significantly lower in the polyamide-treated mice 
(Fig. 4.4B).  
 
 
Figure 4.4 Polyamide 1 demonstrates anti-tumor activity in prostate cancer xenografts. (A) Male 
immunocompromised mice were engrafted with LNCaP cells and observed until tumors reached 
~ 100 mm
3
. Tumor bearing mice were then treated with 20 nmol 1 (n = 12) or vehicle (n = 13) by 
SC injections into the flank distal to the tumor once every three days for a total of three 
injections. Mice were euthanized and tumors resected and weighed two days after final injection. 
Tumors from mice treated with 1 were smaller (mean: 112 mg, median: 94 mg; range: 47–201 
mg) than those of vehicle treated mice (mean: 310 mg, median: 292 mg, range: 173–440 mg). 
Error bars represents max and min, boxes represents the upper and lower quartiles and median. p 
= 1.6 E-5. (B) Serum PSA measured by ELISA pre- and post- treatment. Serum PSA is lower in 
the post-treatment serum of mice treated with 1 as compared to vehicle. p = 0.024. 
 
Perhaps more importantly, tumor-free NSG mice treated with 1 under the same regimen 
showed no signs of physical duress or weight loss, whereas the LNCaP tumor-bearing NSG mice 
exhibited substantial weight loss by the experimental end point (Fig. 4.5). While this host 
toxicity may initially appear undesirable towards cancer therapeutic applications, the observed 
elevation in serum uric acid levels may be an indication of tumor lysis syndrome that is 
commonly associated with rapid tumor cell turnover.
11
 In future studies, a key to overcoming this 
challenge will be finding the optimal polyamide concentration that yields maximum tumor 
reduction but causes minimal toxicity to the host. 
141 
 
 
Figure 4.5 Animal weights were measured at each injection of 1 and at the experimental 
endpoint (EP). (A) Weight measurements of tumor free male immunocompromised mice treated 
with 20 nmol of 1 once every 3 days for 3 injections (n = 5). (B) Weight measurements of 
LNCaP tumor bearing male immunocompromised mice treated with 20 nmol of 1 once every 3 
days for 3 injection (n = 12). (C) Weight measurements of LNCaP tumor bearing male 
immunocompromised mice treated with vehicle (5% DMSO in PBS) once every 3 days for 3 
injections (n = 13). Experiments were end pointed 2 days after last injections. Error bars 
represents max and min, boxes represents the upper and lower quartiles and median. 
 
IV. Transcription Regulation and in vivo Activity of ERE-Targeting Polyamide 3 
 In parallel to our efforts towards polyamide treatment of prostate cancer, Py-Im 
polyamide 3 targeted to the 5’-WGGWCW-3’ sequence found in the estrogen response element 
(ERE) were synthesized and applied towards regulation of estrogen receptor (ER)-mediated 
transcription in T47D-KBLUC breast cancer cells (Fig. 4.6). 
 
Figure 4.6 Chemical structure and binding preferences of 3. (A) Chemical structure and ball-
and-stick representation of 3. (C) Polyamide 3 bound to its match 5’-WGGWCW-3’ sequence. 
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Figure 4.7 Relative mRNA levels of TFF1, TFGB2 and WT1 measured by qRT-PCR. 
Concentrations of 1 are 1.0 μM and 0.3 μM. 
 
 
The genome-wide effects on 17--estradiol (E2)- induced gene expression upon 
treatment with 1 M 3 were analyzed by RNA-seq and confirmed by RT-qPCR (Fig. 4.7). 
Among the subset of E2-activated genes affected by 3, many are important to tumor 
development and therapeutically relevant. In particular, Wilms Tumor 1 (WT1) expression is 
detectable in 90% of breast cancers and high levels of WT1 expression are correlated with poor 
survival rates,
29,30
 while TFF1 is another predictor for breast cancer patient survival.
31
 On the 
other hand, the expression of transforming growth factor- 2 (TGF-2) is strongly repressed by 
E2 and de-repressed three-fold by 3 at 1 M. 32 While these genes most affected by E2 are 
counteracted by 3 in an anti-estrogenic manner, the majority of E2-regulated genes remain 
unresponsive to 3. Furthermore, most of the gene expression changes by 3 are unrelated to E2 
activity, suggesting an alternative mechanism of action. 
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Figure 4.8 Xenograft studies. (A) Treatment of T47D-KBLUC bearing mice with 1 results in 
suppression of ER-driven luciferase. **p < 0.01. n = 12 mice per group. Errors are 95% CI. (B) 
Tumors masses at experimental endpoint were vehicle: 71 ± 12 mg (95% CI); 1: 55 ± 11 mg 
(95% CI). (C) Treatment schedule for extended time-course experiments with normalized mouse 
weights over time. Arrows indicate treatment days. (D) Luciferase signal for polyamide 1 and 
vehicle treated groups. Error bars are standard deviations. Mean tumor masses at the endpoint for 
animals treated with vehicle is 165 ± 27mg (95% CI) and for animals treated with 1 is 128 ± 54 
mg (95% CI). 
 
To further characterize the anti-estrogenic activity of 3 in vivo, T47D-KBLUC cells were 
engrafted into female NSG mice and supplemented with a slow-release subcutaneous E2 pellet in 
the right flank to facilitate E2-induced growth. After one week of growth, the mice were treated 
with either vehicle control or 25 nmol (~ 1.7 mg/kg) polyamide 3 via subcutaneous injection into 
the left flank every other day for a total of four injections. Following three injections, the 
luciferase output increased an average of three-fold for the mice treated with 3, as compared to 
an eight-fold increase for the vehicle treated mice (Fig. 4.8A). The tumors were resected and 
weighed following the fourth injection, and the tumor masses of the mice treated with 1 (55 ± 11 
mg) were found to be comparable to the vehicle controls (71 ± 12 mg) (Fig. 4.14B). To 
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investigate the effects of extended treatment with 3, the same experiment setup was employed 
with a regimen of 9 injections over 25 days. Interestingly, the mice did not lose a significant 
amount of weight (> 15%) until the finals days of treatment (4.8C). Consistent with prior 
findings, the luciferase activity was consistently lower in the mice treatment with 3 (Fig. 4.8D).  
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4.3 Conclusions 
 In light of the regulation of AR-driven gene expression by 1 in LNCaP prostate cancer 
cells, the antitumor activity of 1 have been examined in mice models. The pharmacokinetic and 
toxicity profiles of 1 and 2 have been established in normal mice, and tumor growth inhibition 
was observed in LNCaP-engrafted immunocompromised mice administered with 1 relative to 
untreated controls.  In addition to our studies on the biological effects of 1 in prostate cancer 
models, polyamide 3 designed to bind the ERE has also been shown to downregulate ER-driven 
luciferase signal in T47D-KBLUC breast cancer cell culture and mice xenografts.  
A main challenge in future studies  
Furthermore, preliminary in vivo studies have highlighted the significant changes in 
biological activity resulting from minor structural modifications in both hairpin and cyclic 
polyamides, so another priority will be testing for the right polyamide structure that offers the 
optimal therapeutic window. Finally, other polyamides that have been previously shown to 
modify the gene regulation of other transcription factors, such as HIF-1 and glucocorticoid 
receptor (GR), shall also be examined for their in vivo effects. 
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4.4 Materials and Methods 
 
Materials 
All chemicals were purchased from Sigma-Aldrich, unless otherwise specified. Kaiser 
oxime resin and PyBOP were purchased from NovaBioChem. (R)-3,4-Cbz-Dbu(Boc)-OH was 
purchased from Peptides International. Fmoc-D-Dab(Boc)-OH was purchased from Bachem.  
 
Methods 
Polyamide monomers were obtained using previous protocols.
33
 Microwave-assisted 
coupling reactions were conducted on a Biotage Initiatior Eight synthesizer. Polyamides were 
purified via preparative HPLC on an Agilent Technologies 1200 Series system using a 
Phenomenex Gemini column. Matrix-assisted, LASER desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) was performed on an Applied Biosystems Voyager DR Pro 
spectrometer. NMR spectroscopy data was obtained on a Variant instrument operating at 500 
MHz. Polyamide concentrations were measured in 20% MeCN in 0.1% (v/v) aqueous TFA using 
an approximated extinction coefficient of 69 200 M
-1
 cm
-1
 at λmax near 310 nm.34 
 
 
I. Microwave-Assisted Synthesis of Hairpin Polyamides 
ImImPyPyOH (7). A solution of ImImOH dimer (909 mg, 3.65 mmol) and PyBOP (2.3 g, 4.38 
mmol, 1.2 eq.) in DIEA (1.9 mL, 11.0 mmol) and DMF (5 mL) was stirred for 10 min. The 
solution was then added to HCl•NH2-PyPy-OMe (1.25 g, 3.83 mmol, 1.05 eq.) in DMF (10 mL) 
and stirred at 23 
o
C for 36 h. Upon confirmation of reaction completion by analytical HPLC, this 
solution was then added to dH2O (80 mL) preacidified with aqueous HCl (1N, 11.0 mL, 11.0 
mmol), yielding a precipitate that was isolated by centrifugation (∼4200 rpm). The residual solid 
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was resuspended in dH2O (80 mL), triturated, and collected by centrifugation (repeated 2×) to 
yield 8. Without further purification or drying, this crude material was dissolved in a mixture of 
aqueous NaOH (1N, 40 mL, 40 mmol) and MeOH (40 mL), and stirred at 40
o
C for 16 hr. After 
analytical HPLC confirmed complete saponification, this solution was added to dH2O (40 mL) 
preacidified with aqueous HCl (1 N, 40 mL, 40 mmol), yielding a precipitate that was isolated by 
centrifugation (4200 rpm). The residual solid was resuspended in dH2O (80 mL) and collected by 
centrifugation (repeated 2×). The resultant solid, containing a small amount of residual H2O, was 
frozen and lyophilized to dryness. The dried solid was then triturated with anhydrous Et2O, 
filtered over a sintered glass funnel, washed with copious amounts of anhydrous Et2O, and dried 
in vacuo to yield tetramer 7 as a tan solid (1.5 g, 3.04 mg, 83% yield). 
1
H NMR [499.7 MHz, 
DMSO-d6]: 12.15 (br s, 1 H), 10.36 (s, 1 H), 9.95 (s, 1 H), 9.73 (s, 1 H), 7.57 (s, 1 H), 7.46 (d, 
J = 1.0 Hz, 1 H), 7.43 (d J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1 H), 7.17 (d, J = 2.0 Hz, 1 H), 
7.08 (d, J = 1.0 Hz, 1 H), 6.86 (d, J = 2.0 Hz, 1 H), 4.014 (s, 3 H), 4.011 (s, 3 H), 3.85 (s, 3 H), 
3.82 (s, 3 H). 
 
ImPyPyPy-(R)
-BocHN
-γ-ImPyPyPy-(+)-NH2 (18). Starting with 12 (500 mg, 0.304 mmol), which 
was obtained using published microwave-assisted protocols, the N-terminal Boc group was 
removed by treatment with 80% TFA in DCM for 30 min. The resulting resin was washed with 
DCM (2x), DMF (2x), 20% DIEA in DMF (2x), DMF (2x), MeOH (2x), Et2O (2x), and dried in 
vacuo. -amino turn 9 (402 mg, 0.912 mmol, 3 eq.) was then activated with PyBOP (475 mg, 
0.912 mmol, 3 eq.) and DIEA (320 L, 1.824 mmol, 6 eq.) in DMF (3 mL), and added to the 
deprotected resin in a microwave synthesis vessel.  The coupling reaction was set up in the 
microwave reactor at 60 
o
C for 30 min with constant stirring. The reaction mixture was filtered 
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into a peptide synthesis vessel, and the collected resin was washed with DMF (3x), MeOH (3x), 
Et2O, and dried in vacuo to afford 13. Selective deprotection of the -amino Fmoc group was 
achieved by treatment with 20% piperidine in DMF for 5 cycles x 4 min/cycle, and the resin was 
washed with DMF (2x), MeOH (2x) and Et2O (2x). Tetramer 6 (299 mg, 0.608 mmol, 2.0 eq.) 
was then activated with PyBOP (349 mg, 0.671 mmol, 2.2 eq.) and DIEA (317 l, 1.824 mmol, 
6.0 eq.) in DMF (3 mL), and added to the deprotected resin in a microwave synthesis vessel. The 
coupling reaction was set up in the microwave reactor at 60 
o
C for 5 min with constant stirring. 
The reaction mixture was filtered into a peptide synthesis vessel, and the collected resin was 
washed with DMF (3x), MeOH (3x), Et2O, and dried in vacuo to afford 15 (720 mg). 3,3’-
diamino-N-methyldipropylamine (2 mL) was then added to 15 (240 mg, 0.101 mmol), and the 
resin was cleaved under microwave irradiation at 60
 o
C for two 5-min cycles. The cleavage 
solutions were precipitated with cold Et2O (~ 40 mL), centrifuged (4200 rpm), and the Et2O 
supernatant was decanted to remove excess triamine. The remaining residue was dissolved in 6 
mL 0.1% aqueous TFA at pH ~ 3, purified by reverse-phase HPLC, and lyophilized to dryness to 
afford 18 (41.3 mmol, 41% yield). MALDI-TOF [M+H]
+
 calcd for C62H81N22O11
+
 = 1309.7, 
observed = 1309.9. 
 
ImPyPyPy-(R)
-CbzHN
-γ-ImPyPyPy-(+)-NH2 (19). Starting with 12 (800 mg, 0.487 mmol), which 
was obtained using published microwave-assisted protocols, the N-terminal Boc group was 
removed by treatment with 80% TFA in DCM for 30 min. The resulting resin was washed with 
DCM (2x), DMF (2x), 20% DIEA in DMF (2x), DMF (2x), MeOH (2x), Et2O (2x), and dried in 
vacuo. -amino turn 10 (514 mg, 1.46 mmol, 3 eq.) was then activated with PyBOP (760 mg, 
1.46 mmol, 3 eq.) and DIEA (509 L, 2.92 mmol, 6 eq.) in DMF (3.6 mL), and added to the 
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deprotected resin in a microwave synthesis vessel.  The coupling reaction was set up in the 
microwave reactor at 60 
o
C for 30 min with constant stirring. The reaction mixture was filtered 
into a peptide synthesis vessel, and the collected resin was washed with DMF (3x), MeOH (3x), 
Et2O, and dried in vacuo to afford 14 (970 mg). A fraction of resin 14 (300 mg, 0.151 mmol) was 
then treated with 80% TFA in DCM for 5 min, washed with DCM (2x), DMF (2x), 20% DIEA 
in DMF (2x), DMF (2x), MeOH (2x), Et2O (2x), and dried in vacuo. Tetramer 6 (149 mg, 0.302 
mmol, 2.0 eq.) was activated with PyBOP (236 mg, 0.453 mmol, 3.0 eq.) and DIEA (158 l, 
0.906 mmol, 6 eq.) in DMF (1.2 mL), and added to the deprotected resin in a microwave 
synthesis vessel. The coupling reaction was set up in the microwave reactor at 60 
o
C for 5 min 
with constant stirring. The reaction mixture was filtered into a peptide synthesis vessel, and the 
collected resin was washed with DMF (3x), MeOH (3x), Et2O, and dried in vacuo to afford 16 
(340 mg). 3,3’-diamino-N-methyldipropylamine (1.5 mL) was then added to 15 (170 mg, 0.076 
mmol), and the resin was cleaved under microwave irradiation at 60
 o
C for two 5-min cycles. 
The cleavage solutions were precipitated with cold Et2O (~ 40 mL), centrifuged (4200 rpm), and 
the Et2O supernatant was decanted to remove excess triamine. The remaining residue was 
dissolved in 6 mL 0.1% aqueous TFA at pH ~ 3, purified by reverse-phase HPLC, and 
lyophilized to dryness to afford 19 (27.3 mmol, 36% yield). MALDI-TOF [M+H]
+
 calcd for 
C65H79N22O11
+
 = 1344.6, observed = 1344.8. 
 
ImImPyPy-(R)
-BocHN
-γ-ImPyPyPy-(+)-NH2 (20). Intermediate 13 (0.17 mmol) was prepared 
and deprotected with 20% piperidine in DMF under the same conditions as described for 18. 
Tetramer 7 (168 mg, 0.340 mmol, 2.0 eq.) was then activated with PyBOP (177 mg, 0.340 mmol, 
2.0 eq.) and DIEA (178 L, 1.02 mmol, 6 eq.) in DMF (1.36 mL), and added to the deprotected 
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resin in a microwave synthesis vessel. The coupling reaction was set up in the microwave reactor 
at 60 
o
C for 5 min with constant stirring. The reaction mixture was filtered into a peptide 
synthesis vessel, and the collected resin was washed with DMF (3x), MeOH (3x), Et2O, and 
dried in vacuo to afford 17 (400 mg). 3,3’-diamino-N-methyldipropylamine (1 mL) was then 
added to 17 (135 mg, 0.057 mmol), and the resin was cleaved under microwave irradiation at 60
 
o
C for two 5-min cycles. The cleavage solutions were precipitated with cold Et2O (~ 40 mL), 
centrifuged (4200 rpm), and the Et2O supernatant was decanted to remove excess triamine. The 
remaining residue was dissolved in 6 mL 0.1% aqueous TFA at pH ~ 3, purified by reverse-
phase HPLC, and lyophilized to dryness to afford 20 (29.4 mmol, 52% yield). MALDI-TOF 
[M+H]
+
 calcd for C61H80N23O11
+
 = 1310.6, observed = 1310.7. 
 
ImPyPyPy-(R)
-H2N-γ-ImPyPyPy-(+)-IPA (1). Isophthalic acid (138 mg, 0.83 mmol, 20 eq.) was 
activated with PyBOP (54 mg, 0.103 mmol, 2.5 eq.) in DIEA (145 L, 0.83 mmol, 20 eq.) and 
DMF (8.3 mL), and stirred for 10 min. The activated solution was then added dropwise to a 
solution of 18 (41.3 mol) in DMF (2 mL) and stirred for 30 min. After confirmation of 
complete reaction by analytical HPLC, 40 mL cold Et2O was added to the reaction mixture. The 
solution was then centrifuged at 4200 rpm, followed by removal of the supernatant, and the 
residual material was dried under steady air flow. Neat TFA (1 mL) was added to the oil residue 
and the solution was stirred for 30 min. Upon confirmation of complete deprotection by 
analytical HPLC, the solution was frozen in LN2, diluted with 6 mL dH2O, purified by reverse-
phase HPLC and lyophilized to dryness to yield polyamide 1 (32 mol, 78% yield). MALDI-
TOF [M+H]
+
 calcd for C65H77N22O12
+
 = 1357.6, observed = 1357.9. 
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ImPyPyPy-(R)
-H2N-γ-ImPyPyPy-(+)-IPA (4). Isophthalic acid (56 mg, 0.34 mmol, 20 eq.) was 
activated with PyBOP (22 mg, 0.043 mmol, 2.5 eq.) in DIEA (59 L, 0.34 mmol, 20 eq.) and 
DMF (3.2 mL), and stirred for 10 min. The activated solution was then added dropwise to a 
solution of 19 (17 mol) in DMF (1 mL) and stirred for 30 min. After confirmation of complete 
reaction by analytical HPLC, 40 mL cold Et2O was added to the reaction mixture. The solution 
was then centrifuged at 4200 rpm, followed by removal of the supernatant, and the residual 
material was dried under steady air flow. The resulting oil residue was suspended in 900 L 
TFA, followed by dropwise addition of 100 L TFMSA, and the solution was stirred for 5 min. 
The solution was then frozen in LN2, diluted with 6 mL dH2O, purified by reverse-phase HPLC 
and lyophilized to dryness to yield polyamide 4 (13.4 mol, 79% yield). MALDI-TOF [M+H]+ 
calcd for C65H77N22O12
+
 = 1357.6, observed = 1358.1. 
 
ImImPyPy-(R)
-H2N-γ-ImPyPyPy-(+)-IPA (3). By following the reaction conditions described 
for the synthesis of 1, and using 20 (12.6 mol) instead of 18 as starting material, polyamide 3 
was obtained as an off-white powder (8.9 mol, 71% yield). MALDI-TOF [M+H]+ calcd for 
C64H76N23O12
+
 = 1358.6, observed = 1358.7. 
 
ImPyPyPy-(R)
-AcHN
-γ-ImPyPyPy-(+)-IPA (2). A solution of acetic anhydride (20 L) and 
pyridine (180 L) in DMF (1.8 mL) was added to mol), and stirred for 30 min. After 
confirmation of complete reaction by analytical HPLC, the solution was diluted with 6 mL 
dH2O, purified by reverse-phase HPLC and lyophilized to dryness to afford polyamide 3 (11.4 
mol, 88% yield). MALDI-TOF [M+H]+ calcd for C67H79N22O13
+
 = 1399.6, observed = 1400.0. 
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ImImPyPy-(R)
-AcHN
-γ-ImPyPyPy-(+)-IPA (5). By following the reaction conditions described 
for the synthesis of 2, and using 1 (15.0 mol) instead of 4 as starting material, polyamide 5 was 
obtained as an off-white powder (12.9 mol, 86% yield). MALDI-TOF [M+H]+ calcd for 
C67H78N22O13
+
 = 1400.6, observed = 1400.8. 
 
II. Pharmacokinetic Studies of Polyamides 1 and 2  
 Pharmacokinetic studies were performed by Timothy W. Synold, Bixin Xi, Jun Wu and 
Yun Yen (City of Hope). Sample preparation was performed by Fei Yang (California Institute of 
Technology). Experimental details may be found in: Synold, T. W.; Xi, B.; Wu, J.; Yen, Y.; Li, 
B.C.; Yang, F.; Phillips, J.W.; Nickols, N.G.; Dervan, P.B. “Single-dose pharmacokinetic and 
toxicity analysis of pyrrole-imidazole polyamides in mice” Cancer Chemother. Pharmacol. 
2012, 70, 617–625. 
 
III. Antitumor Activity of Polyamide 1 in Prostate Tumor Xenografts  
 LNCaP tumor xenograft studies were performed by Fei Yang and Nicholas G. Nickols 
(California Institute of Technology). Experimental details may be found in: Yang, F.; Nickols, 
N.G.; Li, B.C.; Marinov, G.; Wold, B. J.; Dervan, P.B. “Antitumor activity of a DNA minor 
groove binding Py-Im polyamide” Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 1863–1868. 
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IV. Transcription Regulation and in vivo Activity of ERE-Targeting Polyamide 3 
 qRT-PCR assays and T47D tumor xenograft studies were performed by Nicholas G. 
Nickols and Jerzy Szablowski (California Institute of Technology). Experimental details may be 
found in: Nickols, N.G.; Szablowski, J.; Hargrove, A.E.; Li, B.C.; Raskatov, J.A.; Dervan, P.B. 
“Activity of a Py-Im polyamide targeted to the estrogen response element” Mol. Cancer Ther. 
accepted (2013). 
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4.6 Experimental Data 
 
 
 
Figure 4.9 Crude HPLC spectra tracing the synthesis of 5 starting from 18. Reverse-phase HPLC 
taken on Beckman Gold instrument equipped with a Phenomenex Gemini analytical column (250 
× 4.6 mm, 5 μm) and a diode array detector, and the mobile phase consisted of a gradient of 
acetonitrile (MeCN) in 0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% 
MeCN, t = 30 s → 18 min]. 
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Figure 4.10 Crude HPLC spectra tracing the synthesis of 2 starting from 19. Reverse-phase 
HPLC taken on Beckman Gold instrument equipped with a Phenomenex Gemini analytical 
column (250 × 4.6 mm, 5 μm) and a diode array detector, and the mobile phase consisted of a 
gradient of acetonitrile (MeCN) in 0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 
80% MeCN, t = 30 s → 18 min]. 
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Figure 4.11 Crude HPLC spectra tracing the synthesis of 3 starting from 20. Reverse-phase 
HPLC taken on Beckman Gold instrument equipped with a Phenomenex Gemini analytical 
column (250 × 4.6 mm, 5 μm) and a diode array detector, and the mobile phase consisted of a 
gradient of acetonitrile (MeCN) in 0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 
80% MeCN, t = 30 s → 18 min]. 
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Table 4.1 Melting temperatures of DNA/polyamide complexes for 1 and 2. All values are 
derived from at least three melting temperature experiments, with standard deviations indicated 
in parentheses. ΔTm values are given as Tm (DNA/polyamide) − Tm (DNA). 
 
 
 
 
Table 4.2 Melting temperatures of DNA/polyamide complexes for 3. All values are derived from 
at least three melting temperature experiments, with standard deviations indicated in parentheses. 
ΔTm values are given as Tm (DNA/polyamide) − Tm (DNA). 
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Alternative Approaches towards Cyclic Polyamide Precursors 
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A.1 Introduction 
 Prior to the discovery of the optimal microwave-assisted conditions on 2-chlorotrityl 
resin, several approaches were explored towards the synthesis of cyclic polyamide 1. Based on 
previously established DPPA-mediated macrocyclization procedures, the main focus was placed 
on effectively obtaining the amino acid precursor 2 (Fig. A.1).
1–3
 Due to the polyaromatic nature 
of these intermediates, solubility remained an issue throughout these efforts, and limited the 
scope of reactions and purification methods that were applicable. The bigger problem, however, 
was the acid-labile C-terminal pyrrole carboxylic acid, which often resulted in decomposition 
products and proved detrimental in several of these attempts. Owing to these challenges, the 
alternative approaches were met with little success and never materialized to a convenient and 
reliable methodology, but nonetheless gave insight into facilitating the eventual development of 
the microwave-assisted solid-phase methods.
4 
 
Figure A.1 Retrosynthesis of cyclic polyamide 1 from linear amino acid precursor 2. 
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A.2 Results and Discussion 
I. Direct Deprotection of Solution-Phase Intermediate 
 In the solution-phase synthesis reported by Chenoweth et al., 3 was rapidly assembled 
prior to activation of the pentafluorophenol ester for macrocyclization.
5
 While the initial 
synthesis proved effective, the cyclization yields were somewhat inconsistent and the substrate 
scope was limited, which created the need for a more reliable and divergent approach. As the 
DPPA-mediated macrocyclization procedure was proven to be an effective route towards 
synthesizing cyclic polyamides, the first attempt towards the amino acid precursor was made by 
directly deprotecting the N-terminal Boc group in 3 under acidic conditions (Scheme A.1).  
 
Scheme A.1 Direct deprotection of 3 under acidic conditions 
 
1
Reagents and conditions: (i) 3M HCl in EtOAc, -40
o
C, 8h, 31% yield.  
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 Unfortunately, the C-terminal pyrrole carboxylic acid proved to be extremely labile under 
acidic conditions, often resulting in decomposition products at temperatures higher than -40
o
C 
(Fig. SA.1–3). This method was not only required constant temperature control, but the yields 
were also largely irreproducible. Further attempts to first protect the C-terminus as either a 
trimethylsilylethyl (TMSE) or fluorenylmethyl (Fm) ester resulted in decomposition as well. 
 
II. Solid-Phase Synthesis on HFMS Resin 
 In light of the acid sensitivity of the pyrrole carboxylic acid, and in efforts to create a 
more time-efficient and divergent strategy, we began investigating solid-phase methods using the 
base-labile [9-hydroxymethyl-2-fluorenyl] succinamic acid (HMFS) resin.
6
 Prior to solid-phase 
assembly, HMFS phenacyl (Pac) ester was first synthesized using published conditions and pre-
conjugated to the initial BocPyOH monomer to yield 5 (Scheme A.2).
7 
 
Scheme A.2 Synthesis of Boc-Py-HMFS-OH linker 6 
 
1
Reagents and conditions: (i) BocPyOH, EDC, DMAP, DCM; (ii) Zn(0), AcOH. 
 
After removal of the Pac ester, 6 was then loaded onto MBHA resin for the polyamide 
core 7 was quickly assembled using oligomer intermediates under microwave-assisted conditions 
(Scheme A.3).
8
 While HPLC spectra of 7 indicated relative high purity, deprotection of the C-
terminal Boc group with 80% TFA prior to final resin cleavage still resulted in decomposition. 
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Scheme A.3 Microwave-assisted synthesis of 8 on HMFS resin 
 
1
Reagents and conditions: (i) 6, PyBOP, DIEA, NMP, m.w. 80 
o
C, 2 h; (ii) 80% TFA, DCM, 23 
o
C, 5 min. 
 
 Owing to this high sensitivity to acidic conditions, a subsequent attempt was made to 
protect the second turn unit with a terminal Fmoc group. Since the synthesis of N-Fmoc 
oligomers have not been established, this was performed in a monomer-by-monomer fashion. 
Unfortunately, deprotection of the second imidazole unit with TFA again resulted in 
decomposition (Scheme A.4). Overall, the decomposition observed in various conditions using 
HMFS resin, as well as the synthetic rigor required in the initial loading, rendered this approach 
impractical towards extensive scale-up for biological studies. 
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Scheme A.4 Microwave-assisted synthesis on HMFS resin 
 
1
Reagents and conditions: (i) 80% TFA, DCM, 23 
o
C, 25 min. 
 
III. Two-Step Cleavage off Oxime Resin  
 Given our extensive experience with oxime resin, an effective cleavage method to obtain 
a C-terminal carboxylic acid would allow us to take advantage of pre-existing solid-phase 
technologies towards cyclic polyamide precursors.
8,9
 Unfortunately, typical methods using 
aqueous 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) resulted in product decomposition and gave 
rise to concerns over epimerizing the -amino stereocenters on the turn units.10 Alternatively, C-
terminal carboxylic acids may be obtained from oxime resin using a two-step procedure 
involving initial cleavage with N-hydroxypiperidine (HOPip) and subsequent Zn-catalyzed 
removal of the HOPip ester.
11–13
 Using optimized microwave-assisted conditions, 11 was rapidly 
assembled and subjected to these conditions (Scheme A.5). 
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Scheme A.5 Two-step cleavage of 11 off Kaiser oxime resin 
 
1
Reagents and conditions: (i) HOPip, DMF, 23
o
C, 24 h; (ii) Zn(0), 90% AcOH, 16% yield overall. 
 
The analytical HPLC spectra of both the intermediate 12 and precursor 2 were relatively 
clean, indicating a limited amount of decomposition. Due to technical difficulties in isolating 2, 
however, the intermediate was only recovered in a modest 16% yield. Also, despite a deliberate 
filtration procedure, the generation of water-insoluble zinc products rendered this procedure 
undesirable for reverse-phase HPLC purification. While the recovery yields were less than ideal 
and the work-up was considerably labor intensive, this nonetheless set a firm baseline for the 
development of solid-phase techniques towards cyclic polyamide precursors, and may in itself be 
useful for small-scale divergent syntheses of hairpin and cyclic polyamides. 
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A.3 Conclusions 
 Multiple approaches were attempted towards the synthesis of cyclic polyamide precursor 
2. Direct deprotection of solution-phase intermediate 3 under acidic conditions resulted in 
decomposition, even at -40 
o
C. Due to this observed acid sensitivity of the C-terminal carboxylic 
acid, solid-phase synthesis of 2 on the base-labile HMFS resin was tried. Boc deprotection of the 
final resin intermediate 7 again led to decomposition, whereas efforts towards replacing the 
terminal Boc group with Fmoc was also unsuccessful. Using a two-step cleavage procedure, 2 
was synthesized on Kaiser oxime resin under microwave-irradiation and isolated in 16% yield. 
While the recovery was modest, this was at the time an otherwise acceptable method, but the use 
of water-insoluble zinc during cleavage raised concerns regarding potential long-term damage to 
our reverse-phase HPLC systems. Ultimately, although none of these ventures directly resulted 
in success, these failed attempts highlighted some of the challenges towards synthesizing the 
zwiterrionic polyaromatic intermediates. Perhaps most importantly, the more commonly used 
Boc protection scheme was proven infeasible, which led to the eventual development of 
microwave-assisted methods on 2-chlorotrityl resin using Fmoc chemistry. 
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A.4 Materials and Methods 
Materials 
All chemicals were purchased from Sigma-Aldrich, unless otherwise specified. Kaiser 
oxime resin and PyBOP were purchased from NovaBioChem. (R)-3,4-Cbz-Dbu(Boc)-OH was 
purchased from Peptides International. MBHA resin was purchased from Bachem.  
 
Methods 
Polyamide monomers were obtained using previous protocols.
33
 Microwave-assisted 
coupling reactions were conducted on a Biotage Initiatior Eight synthesizer. Polyamides were 
purified via preparative HPLC on an Agilent Technologies 1200 Series system using a 
Phenomenex Gemini column. Matrix-assisted, LASER desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) was performed on an Applied Biosystems Voyager DR Pro 
spectrometer. NMR spectroscopy data was obtained on a Variant instrument operating at 500 
MHz. Polyamide concentrations were measured in 20% MeCN in 0.1% (v/v) aqueous TFA using 
an approximated extinction coefficient of 69 200 M
-1
 cm
-1
 at λmax near 310 nm.34 
 
I.  Direct Deprotection of Solution-Phase Intermediate 
 Boc-protected intermediate 3 obtained from previous procedures
5
 was subjected to either 
25% TFA in DCM or 4 M HCl in 1,4-dioxane at 23 
o
C, which resulted in rapid decomposition 
(Fig. SA.1 & SA.2). Similar conditions were then repeated at -40 
o
C with improved recovery, but 
required constant temperature control for extended periods of times (6 to 8 h) (Fig. SA.3). The 
best conditions were illustrated in Scheme A.1 and described as follows: 
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A solution of 2 (20 mg, 12.6 mol) in EtOAc (1.8 mL) was first cooled to -40oC, 
followed by dropwise addition of 3M HCl in EtOAc (200 L) at -40oC. The reaction mixture 
was then stirred at -40 
o
C for 8 h. Upon confirmation of complete deprotection by analytical 
HPLC, the solution was frozen in LN2, thawed in DMF, and the EtOAc was removed in vacuo. 
The remaining solution was then diluted in 6 mL 20% AcN in 0.1% aqueous TFA, purified by 
reverse-phase HPLC and lyophilized to dryness to afford precursor 2 (3.9 mol, 31% yield). 
MALDI-TOF [M+H]
+
 calcd for C70H77N22O15
+
 = 1465.4, observed = 1465.7. 
 
II. Solid-Phase Synthesis on HFMS Resin 
Boc-Py-HMFS-OPac (5). A solution of BocPyOH (504 mg, 2.10 mmol, 6.0 eq.) and EDCI (201 
mg, 1.05 mmol, 3.0 eq.) in DCM (720 L) was stirred at 23 oC for 1 h. The activated mixture 
was then added dropwise to a solution of 4 (150 mg, 0.350 mmol) in DCM (480 L), followed 
by DMAP (43 mg, 0.350 mmol, 1.0 eq.), and stirred for 23 
o
C for 40 h. The reaction mixture was 
then diluted with DCM (2 mL) and purified by silica gel chromatography (DCM to 4:1 DCM: 
EtOAc). The desired fractions were combined, concentrated and dried to afford 5 as a tan solid 
(173 mg, 0.266 mmol, 76% yield). 
1
H NMR [499.8 MHz, DMSO-d6]:  10.13 (s, 1 H), 9.04 (s, 1 
H), 7.95 (m, 3 H), 7.80 (app d, J = 7.5 Hz, 2 H), 7.68 (app t, 1 H), 7.61 (m, 2 H), 7.55 (app t, J = 
7.5 Hz,  2 H), 7.38 (app t, J = 7.5 Hz, 1 H), 7.26 (app t, J =  7.5 Hz, 1 H), 7.06 (s, 1 H), 6.59 (s, 1 
H), 5.50 (s, 2 H), 4.71 (app dd, J = 5 Hz, J = 10 Hz, 1 H), 4.34 (m, 2 H), 3.56 (s, 3 H), 2.77 (t, 2 
H), 2.69 (t, 2 H), 1.42 (s, 9 H). 
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Boc-Py-HMFS-OH (6). A solution of 5 (145 mg, 0.223 mmol) in AcOH (1 mL) was treated 
with zinc dust (291 mg, 4.45 mmol, 20 eq.) and stirred at 40 
o
C for 30 min. The solution was 
then filtered, and the filtrate was concentrated in vacuo. The residual oil was resuspended in 
EtOAc, washed with 1M HCl, dH2O (3x), brine, dried (MgSO4), filtered and concentrated to 
afford 6 as an off-white solid (118 mg, 0.223 mmol, 99% yield). 
1
H NMR [499.8 MHz, DMSO-
d6]:  12.10 (s, 1 H), 10.12 (s, 1 H), 9.06 (s, 1 H), 7.94 (m, 1 H), 7.79 (app d, J =  8.0 Hz, 2 H), 
7.61 (app t, J = 8.0 Hz, 2 H), 7.37 (t, J = 7.5 Hz, 1 H), 7.26 (app t, J = 7.5 Hz, 1 H), 7.07 (s, 1 H), 
6.60 (s, 1 H), 4.68 (m, 1 H), 4.34 (m, 2 H), 3.57 (s, 3 H), 2.52-2.57 (m, 4 H), 1.42 (s, 9 H). 
 
Boc-Py-HMFS-MBHA Resin. MBHA resin (100 mg, 0.076 mmol) was first washed with a 2:1 
DMF:DIEA solution, MeOH (2x), and dried in vacuo. A solution of 6 (118 mg, 0.223 mmol, 2.9 
eq.) and PyBOP (118 mg, 0.228 mmol, 3.0 eq.) in DIEA (79 L, 0.456 mmol, 6.0 eq.) and NMP 
(550 L) was stirred at 23 oC for 10 min, and then treated with the pre-washed MBHA resin. The 
reaction mixture was submitted to microwave irradiation at 80 
o
C for 2 h. The resin was then 
filtered and washed with NMP (2x), DCM (2x), NMP (2x), MeOH (2x), and dried in vacuo. 
Complete loading of the resin was confirmed by the Kaiser test. 
 
Microwave-Assisted Solid-Phase Synthesis (7–10).  Polyamide cores 7 and 9 were assembled on 
Boc-Py-HMFS-MBHA resin with the corresponding monomers using published microwave 
conditions.
8
 For 7, the Im-turn unit was introduced as a dimer.
5,14
 As illustrated in Figures A.3 
and A.4, TFA deprotection of the N-terminal Boc groups in 7 and 9 to yield 8 and 10 resulted in 
decomposition. 
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III. Two-Step Cleavage off Oxime Resin 
 A solution of HOPip (22 mg, 0.21 mmol, 10 eq.) in DMF (200 L) was added to 11 (60 
mg, 21 mol) and stirred at 23 oC for 24 h. The mixture was then filtered, and the resin was 
resubmitted to fresh solution of HOPip (22 mg, 0.21 mmol, 10 eq.) in DMF (200 L) and stirred 
for another 24 h. The mixture was again filtered and cold Et2O was added to the combined 
filtrate, yielding a precipitate that was isolated by centrifugation. The crude 1-piperidyl ester 12 
was then dissolved in 90% AcOH (5 mL) and stirred vigorously with Zn dust (100 mg) at 23 
o
C 
for 1 h. The mixture was then filtered and washed with 90% AcOH (5 mL). The combined 
filtrate was concentrated in vacuo, and the residue was redissolved in 6 mL 30% AcN in 0.1% 
aqueous TFA. Remaining Zn precipitate was then removed by centrifugation, and the 
supernatant was purified by reverse-phase HPLC and lyophilized to dryness to yield 2 as a light 
yellow solid (3.4 mol, 16% yield). MALDI-TOF [M+Na]+ calcd for C70H7N22NaO15
+
 = 1487.6, 
observed = 1487.8.  
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A.6 Experimental Data 
 
Scheme A.6 Direct deprotection of 3 with TFA at room temperature 
 
 
 
1
Reagents and conditions: (i) 25% TFA, DCM, 23 
o
C, 10 min. 
2
 Reverse-phase HPLC taken on Beckman Gold instrument equipped with a Phenomenex Gemini analytical column 
(250 × 4.6 mm, 5 μm) and a diode array detector, and the mobile phase consisted of a gradient of acetonitrile 
(MeCN) in 0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Scheme A.7 Direct deprotection of 3 with HCl at room temperature 
 
 
 
1
Reagents and conditions: (i) 4M HCl in 1,4-dioxane, 23 
o
C, 30 min. 
2
Reverse-phase HPLC taken on Beckman Gold instrument equipped with a Phenomenex Gemini analytical column 
(250 × 4.6 mm, 5 μm) and a diode array detector, and the mobile phase consisted of a gradient of acetonitrile 
(MeCN) in 0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
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Scheme A.8 Direct deprotection of 3 with HCl at -40 
o
C 
 
 
 
1
Reagents and conditions: (i) 25% TFA, DCM, -40 
o
C, 6 h. 
2
 Reverse-phase HPLC taken on Beckman Gold instrument equipped with a Phenomenex Gemini analytical column 
(250 × 4.6 mm, 5 μm) and a diode array detector, and the mobile phase consisted of a gradient of acetonitrile 
(MeCN) in 0.1% (v/v) aqueous TFA [10% MeCN, t = 0 → 30 s; 10% → 80% MeCN, t = 30 s → 18 min]. 
